“No published study was identified that tested this specific intervention, dose strategy, mechanism, disease model, and sex-stratified design as of the protocol search date.”

Ranked M.Pharm pharmacology animal-study topics

Best 3 choices for a typical M.Pharm laboratory

1. Diabetic neuropathy plus ferroptosis

• Reliable, affordable animal model.
• Multiple pharmacological endpoints.
• Clear positive control: pregabalin or duloxetine.
• Can generate behavioural, biochemical, molecular and histopathology data.
• Good publication potential if you include both sexes and a predefined ferroptosis panel.

2. Postbiotic therapy in chemotherapy-induced neuropathy

• Less crowded than generic antioxidant or herbal neuropathy projects.
• Strong mechanism: gut barrier to systemic inflammation to neuroinflammation to pain.
• Relevant to cancer supportive care.
• Avoid vague “probiotic” products. Use a defined, reproducible postbiotic or purified metabolite.

3. Opioid-induced bowel dysfunction combination therapy

• Clear clinical problem and straightforward endpoints.
• Lets you show that gastrointestinal protection does not reduce central analgesia.
• Offers a convincing combination-therapy publication angle.

How to make the work genuinely novel

1. Disease model: Use a clinically relevant model, not only an acute screening model.
2. Test drug: Prefer a standardised compound, repurposed drug, or well-characterised fraction.
3. Mechanism: Pre-specify one pathway, for example ferroptosis, NLRP3, gut permeability, or senescence.
4. Comparator: Include standard treatment such as pregabalin, duloxetine, diclofenac, or metformin as appropriate.
5. Sex: Include male and female animals if feasible, with sex-stratified analysis.
6. Functional endpoint: Include meaningful function, not only biochemical markers.
7. Safety: Add body weight, organ weight, serum biochemistry and target-organ histology.
8. Study quality: Randomisation, blinded outcome assessment, sample-size rationale, preregistered primary endpoint and ARRIVE 2.0 reporting.

Avoid these overdone M.Pharm topics

• “Antidiabetic activity of plant extract in STZ rats”
• “Anti-inflammatory activity using carrageenan paw oedema only”
• “Antioxidant activity of herbal formulation”
• “Antidepressant activity by forced-swim test only”
• “Hepatoprotective activity in paracetamol model”
• “Antiulcer activity in pylorus ligation”
• “Anticancer activity of a plant extract without target validation”
• “Nootropic activity using only scopolamine-induced amnesia”

Practical novelty-search protocol before finalising

("disease model") AND ("candidate drug/intervention") AND
("mechanism") AND (rat OR mouse OR animal)

("paclitaxel induced neuropathy") AND postbiotic AND NLRP3 AND rat

“A structured search was performed on [date] across PubMed, Scopus and Google Scholar. No study was identified evaluating [exact intervention] in [exact model] with simultaneous assessment of [functional endpoint] and [mechanistic biomarkers].”

My strongest recommendation

• IAEC/CPCSEA approval and animal-house access
• Animal cages, weighing balance, oral gavage needles, basic lab consumables
• Behavioural apparatus such as hot plate, actophotometer, elevated plus maze, or rotarod
• Faculty supervision and standard laboratory instruments

Best low-cost M.Pharm animal pharmacology topic

Recommended title

Why this is suitable

• Low cost: metformin and paracetamol are inexpensive generic medicines.
• Model is affordable: formalin test needs minimal reagents and gives two pain phases, early neurogenic pain and late inflammatory pain.
• Novelty is realistic: rather than claiming a new drug effect, test whether the combination, sex, and dosing time alter analgesic response.
• Pharmacology value: evaluates drug repurposing and combination therapy.
• Publication potential: better than a routine “plant extract has analgesic activity” study if randomisation, blinding and proper controls are used.
• No expensive biomarkers required: outcomes are observable pain behaviour and locomotor activity.

Simple design

1. Vehicle control
2. Paracetamol standard group
3. Metformin low-dose group
4. Metformin plus paracetamol low-dose combination
5. Combination administered in morning
6. Combination administered in evening

• Best option: male and female comparison
• Second option: morning versus evening dosing comparison

Main outcomes

• Formalin-induced paw-licking or paw-biting time in early and late phases
• Percentage inhibition of nociceptive behaviour
• Locomotor activity or rotarod assessment to show that reduced pain behaviour is not simply sedation or motor impairment
• Body-weight monitoring and gross toxicity observation

Approximate ₹10,000 budget

Other feasible ₹10k topics

1. Low-dose combination analgesia

• Very cheap and easy.
• But less novel than the metformin combination.
• Improve it by comparing male versus female animals.

2. Anti-inflammatory chronopharmacology

• Low cost if rats are available.
• Measures paw volume at fixed intervals.
• Add gastric-ulcer scoring only if facilities and IAEC approval permit.
• This is more feasible than advanced molecular projects but has moderate novelty.

3. Repurposing in acute inflammatory pain

• Cheapest option.
• Two complementary tests make the work stronger.
• Its gap is the low-dose combination and sex-stratified design, not the individual tests themselves.

4. CNS side-effect-aware analgesic screening

• Clinically relevant combination strategy.
• Include formalin test plus rotarod or actophotometer.
• Pregabalin can increase the cost slightly.

Best choice under ₹10k

“Sex-dependent antinociceptive interaction of low-dose metformin and paracetamol in formalin-induced persistent pain in Swiss albino mice.”

Important wording for your synopsis

“The available literature will be searched systematically to identify whether low-dose metformin-paracetamol combination therapy has been evaluated in formalin-induced persistent pain with sex-stratified behavioural and motor-safety outcomes. The proposed study addresses this specific evidence gap.”

Top low-cost topics, ranked

My top 5 recommendations

1. Metformin plus paracetamol in persistent pain

• Both medicines are cheap and easily available.
• Formalin gives early neurogenic and late inflammatory pain phases.
• A combination-treatment design is more useful than testing one common drug alone.
• You can add male-female comparison without expensive assays.
• Include an actophotometer or rotarod to exclude sedation/motor impairment.

---

2. Chronopharmacology of paracetamol

• Cheapest among good-quality topics.
• Same drug, same model, but different dosing time.
• Requires no ELISA, histology, PCR, or costly chemicals.
• Easy to explain in viva: biological rhythms may alter drug response.

---

3. Paracetamol plus caffeine in inflammatory pain

• Both drugs are low-cost.
• Clinically relevant because such combinations are used for pain.
• Easy endpoints.
• Better than a routine analgesic screening project because it evaluates both efficacy and motor safety.

---

4. Metformin plus diclofenac

• Adds anti-inflammatory and analgesic endpoints.
• Carrageenan paw oedema is simple if plethysmometer facilities are available.
• Metformin repurposing gives the project a modern pharmacology angle.

---

5. Diclofenac chronopharmacology with gastric safety

• Balances benefit and adverse effect, which is better pharmacology than efficacy alone.
• Uses readily available drugs and routine gastric ulcer scoring.
• Has a clinically relevant question: can dosing time improve efficacy-to-toxicity balance?

Lowest-cost options

1. Paracetamol morning versus evening study
2. Paracetamol-caffeine combination study
3. Metformin-paracetamol combination study
4. Paracetamol pretreatment-time study

How to increase the rating of any topic

• A standard-drug comparator
• One motor-safety test
• Random allocation of animals
• Blinded scoring of behavioural outcomes
• A defined primary endpoint
• Clear inclusion/exclusion criteria
• Body-weight and general-toxicity monitoring
• Male-female comparison or dosing-time comparison, but not both if the sample size becomes too small

Topics to avoid on a ₹10k budget

• Diabetic neuropathy with biochemical markers
• Parkinsonism, Alzheimer’s or stroke models
• Cancer models
• Microbiome, probiotics or postbiotics
• Ferroptosis, NLRP3, cytokines, ELISA, PCR, Western blot studies
• Nanoformulation projects
• Projects requiring histopathology if your institution charges separately
• Any herbal extract project without botanical authentication and standardisation

Best final selection

“Sex-dependent antinociceptive interaction of low-dose metformin and paracetamol in formalin-induced persistent pain in Swiss albino mice.”

“Influence of administration time on paracetamol analgesia in formalin-induced inflammatory pain in Swiss albino mice.”

Best final choice: Topic 3

Improved project title

“with assessment of pharmacodynamic interaction and motor safety.”

Why this is the best

• Looks more advanced than a simple analgesic screening study.
• Uses drug repurposing: metformin is an antidiabetic drug assessed as an adjunct analgesic.
• Uses a clinically meaningful question: can metformin allow a lower effective paracetamol dose?
• Can be completed in the ₹7,000 to ₹10,000 range if animal-house infrastructure is available.
• You can demonstrate a real pharmacology concept: additive, synergistic, or sub-additive interaction.
• The formalin model has two phases, allowing discussion of neurogenic versus inflammatory pain.
• Add rotarod or actophotometer testing, showing that reduced pain behaviour is not due to sedation or motor impairment.
• A 2025 mouse study reports that metformin reduces inflammatory nociception, so your project should focus on the specific low-dose metformin plus paracetamol interaction, rather than merely asking whether metformin is analgesic. See the 2025 metformin study.

Why externals will like it

“This is not a routine analgesic study. We assessed whether repurposed low-dose metformin can enhance paracetamol analgesia in persistent inflammatory pain, potentially reducing the required paracetamol dose and its dose-related toxicity. We also distinguished analgesia from motor impairment.”

---

Ranking of your five topics for an external examiner

Why not select the other options?

1. Diabetic neuropathy plus ferroptosis

2. Postbiotic treatment in chemotherapy-induced neuropathy

3. Chronopharmacology of paracetamol

4. Paracetamol plus caffeine

---

Proposed objectives for the selected topic

Final title for synopsis

Objectives

1. To evaluate the antinociceptive effect of low-dose metformin in the formalin test.
2. To evaluate the antinociceptive effect of a sub-effective or low dose of paracetamol.
3. To assess whether their combination produces additive or synergistic antinociception.
4. To compare effects in the early neurogenic phase and late inflammatory phase of the formalin test.
5. To assess locomotor coordination using rotarod or actophotometer.
6. To monitor body weight, gross toxicity signs and mortality during the study.

Minimal group plan

1. Vehicle control
2. Paracetamol low-dose
3. Metformin low-dose
4. Metformin plus paracetamol low-dose
5. Standard-dose paracetamol reference group

One important upgrade that impresses an external

• Additive
• Synergistic
• Antagonistic

What to tell the external in viva

“Metformin has emerging evidence of antinociceptive activity, but its ability to reduce the dose requirement of paracetamol in persistent inflammatory pain has not been adequately defined in our selected model. We therefore evaluated a low-dose combination, included a standard comparator, used separate neurogenic and inflammatory formalin phases, and checked motor safety to exclude false analgesic results caused by reduced movement.”

Best additional project ideas

Top three choices to impress an external

1. Metformin plus paracetamol

“Evaluation of the paracetamol-sparing effect of low-dose metformin in formalin-induced persistent inflammatory pain in Swiss albino mice.”

• Drug repurposing
• Rational combination pharmacology
• Dose-sparing potential
• A persistent inflammatory-pain model
• Motor-safety assessment
• Possibility of additive versus synergistic interaction analysis

2. Melatonin for NSAID gastric safety

“Evaluation of melatonin as a gastroprotective adjunct against diclofenac-induced gastric injury while preserving anti-inflammatory efficacy in rats.”

• Efficacy: reduction in inflammation
• Safety: prevention of NSAID-induced gastric damage

3. Chronopharmacology of diclofenac

“Chronopharmacological evaluation of diclofenac: influence of administration time on anti-inflammatory efficacy and acute gastric injury in rats.”

Which ideas are safest for your budget?

Very safe within ₹10k

• Paracetamol chronopharmacology
• Metformin-paracetamol combination
• Melatonin-paracetamol combination
• Paracetamol plus vitamin C
• Oral versus intraperitoneal paracetamol comparison
• Paracetamol-caffeine combination

Possible within ₹10k but confirm animal-house charges first

• Diclofenac gastric-safety studies
• Famotidine-diclofenac studies
• Melatonin-diclofenac gastroprotection
• Carrageenan plus ulcer-model projects

Avoid these, even though they sound advanced

• “Diabetic neuropathy with ferroptosis” without GPx4, SLC7A11, lipid-peroxidation, iron, or related assays
• “Postbiotic treatment in chemotherapy-induced neuropathy” without defined postbiotic characterisation or gut/inflammatory analysis
• “Antioxidant mechanism” without reliable biochemical measurements
• “Anti-inflammatory herbal extract” with only carrageenan paw oedema
• Any project that claims molecular mechanisms without molecular or biochemical evidence

How to make a low-cost topic look high quality

1. One strong research question
   • Example: “Can metformin reduce the paracetamol dose needed for inflammatory pain control?”
2. One primary outcome
   • Example: late-phase paw-licking time in the formalin test.
3. One safety outcome
   • Example: rotarod or actophotometer performance.
4. A standard comparator
   • Use standard-dose paracetamol or diclofenac where appropriate.
5. Good experimental design
   • Random allocation
   • Blinded scoring
   • Predefined inclusion/exclusion criteria
   • Appropriate statistical plan
   • No unnecessary animal groups

Final shortlist

1. Low-dose metformin as a paracetamol-sparing adjuvant in formalin-induced persistent inflammatory pain
2. Melatonin protection against diclofenac-induced gastric injury while retaining anti-inflammatory action
3. Chronopharmacological effect of diclofenac on inflammation and gastric injury

New low-cost topic ideas with ratings

Best 5 newer choices

1. Melatonin plus paracetamol in persistent pain

“Evaluation of the paracetamol-sparing effect of low-dose melatonin in formalin-induced persistent inflammatory pain in Swiss albino mice.”

• Rational multimodal analgesia approach.
• Melatonin allows discussion of pain modulation, sleep-pain interaction, oxidative stress, and chronopharmacology.
• Inexpensive drugs and simple animal model.
• Add rotarod/actophotometer to demonstrate that apparent analgesia is not due to sedation.

---

2. Famotidine versus pantoprazole in NSAID gastric injury

“Comparative evaluation of famotidine and pantoprazole against diclofenac-induced gastric injury in rats.”

• Clinically relevant safety-pharmacology topic.
• Includes a direct comparison of two common gastroprotective approaches.
• Easy outcomes: ulcer index, number and severity of lesions, gastric pH if the facility permits.
• Better than only testing “anti-ulcer activity” of one drug.

---

3. Pyridoxine plus paracetamol

“Evaluation of pyridoxine as a low-cost adjunct to paracetamol in formalin-induced inflammatory pain in mice.”

• Very low-cost.
• Vitamin B6 gives a plausible neuropharmacology discussion.
• More original than paracetamol-caffeine.
• Easy to complete with formalin testing and motor-safety testing.

---

4. Dosing interval, efficacy and toxicity of diclofenac

“Influence of dosing interval on the anti-inflammatory efficacy and acute gastric injury profile of diclofenac in rats.”

• Studies both efficacy and safety.
• Lets you discuss benefit-risk balance and rational dosing.
• Looks more advanced than a plain carrageenan paw-oedema project.

---

5. Metformin in visceral pain

“Evaluation of the antinociceptive and motor-safety profile of low-dose metformin in acetic-acid-induced visceral pain in Swiss albino mice.”

• One of the cheapest models.
• Repurposing angle makes the project more current.
• Add formalin test if funds allow, so that you have two complementary pain models.

Best topics depending on your external examiner

My updated top 3 under ₹10,000

1. Metformin plus paracetamol in formalin-induced persistent pain - 9.2/10
2. Melatonin plus paracetamol in formalin-induced persistent pain - 8.9/10
3. Famotidine versus pantoprazole against diclofenac-induced gastric injury - 8.6/10

One topic I would choose if I were you

“Evaluation of the paracetamol-sparing effect of low-dose metformin in formalin-induced persistent inflammatory pain in Swiss albino mice, with motor-safety assessment.”

• A clear clinical question
• Drug repurposing
• Combination pharmacology
• Low expense
• Easy, defendable endpoints
• A good opportunity to discuss dose-sparing and pharmacodynamic interaction

“A systematic literature search will determine whether this exact drug combination, dose design, animal model, and outcome set has previously been reported.”

Different M.Pharm pharmacology project ideas

Best completely different ideas for your external

1. Best overall: stress, stomach injury and behaviour

“Evaluation of propranolol as a repurposed agent in restraint stress-induced gastric injury and behavioural alteration in Swiss albino mice.”

• It links the brain-gut axis, stress pharmacology, autonomic system, and ulcer pharmacology.
• It is more interesting than only doing an ulcer index.
• Propranolol is cheap and familiar, but its role in your exact integrated model can be the research gap.
• You can discuss sympathetic activation, catecholamines, stress-induced gastric mucosal injury, and behavioural outcomes.

---

2. Best metabolic-CNS project

“Effect of short-term metformin treatment on high-fat-diet-induced glucose intolerance and anxiety-like behaviour in mice.”

• Combines metabolic dysfunction and behavioural pharmacology.
• Modern angle: metabolic disease can affect mental health-related behaviour.
• Has two meaningful outcomes: glucose regulation and anxiety-like behaviour.
• More advanced than a basic antidiabetic project.

---

3. Smart and very low-cost: metformin chronopharmacology

“Chronopharmacological evaluation of metformin on oral glucose tolerance in Swiss albino mice.”

• Uses a modern concept: drug response may vary with biological timing.
• Low reagent and drug cost.
• Strong viva points: circadian rhythms, glucose metabolism, pharmacodynamics, and rational dosing time.
• Does not need expensive biochemical kits if glucose estimation is available.

---

4. Different and practical: caffeine withdrawal model

“Evaluation of behavioural and locomotor consequences of short-term caffeine withdrawal in Swiss albino mice.”

• Very inexpensive.
• Relevant to a widely consumed psychoactive substance.
• You can discuss adenosine receptors, dependence, withdrawal, anxiety, and motor activity.
• Better if you compare caffeine exposure, withdrawal, and control groups.

---

5. Strong CNS option: seizure threshold

“Evaluation of pyridoxine pretreatment on pentylenetetrazole-induced seizure threshold in Swiss albino mice.”

• Moves away from routine pain studies.
• Good neuropharmacology discussion: GABA synthesis, seizure threshold, and anticonvulsant screening.
• Uses inexpensive drugs and clear endpoints.

My final new top 5

1. Propranolol in restraint-stress-induced gastric injury and behavioural alteration - 9.0/10
2. Metformin in high-fat-diet glucose intolerance plus anxiety-like behaviour - 8.9/10
3. Chronopharmacology of metformin in oral glucose tolerance - 8.8/10
4. Pyridoxine plus metformin in glucose intolerance - 8.7/10
5. Caffeine withdrawal and anxiety-like behaviour - 8.6/10

Best one to submit to your guide

“Evaluation of propranolol as a repurposed agent in restraint stress-induced gastric injury and behavioural alteration in Swiss albino mice.”

“Stress activates sympathetic and neuroendocrine pathways that may affect both behaviour and gastric mucosal integrity. This project evaluates whether modulation of adrenergic signalling alters these linked stress outcomes.”

Best different rat-based project topics under ₹10k

Best topic for rat and external examiner

Recommended final title

Why it can impress an external

• It is a direct comparison of two clinically relevant drug classes: H2-receptor blocker versus proton-pump inhibitor.
• It uses a clinically meaningful stress-related ulcer model, rather than only a routine acid-secretion model.
• You can discuss stress physiology, autonomic activation, gastric acid, mucosal defence, and comparative pharmacology.
• Endpoints are objective and affordable: ulcer index, lesion number/severity, gastric pH, and acidity if your laboratory permits.
• It is much more feasible than ferroptosis or chemotherapy-neuropathy projects.

Best if you want a modern, clean project with minimum cost

Title

Why it is strong

• Modern concept: drug response may change with dosing time.
• Very low drug and reagent cost.
• Clear numerical data: fasting glucose, post-glucose values, glucose AUC.
• Easy to explain in viva: circadian rhythm, glucose metabolism, pharmacodynamics, and rational timing of therapy.
• Less invasive and ethically simpler than ulcer or seizure models.

Best CNS-focused rat project

Title

Topics I would avoid with rats under ₹10k

• Streptozotocin diabetes plus neuropathy projects
• High-fat diet metabolic syndrome models
• Chronic unpredictable stress for many weeks
• Histopathology-dependent topics if external pathology fees apply
• ELISA, cytokine, oxidative stress, ferroptosis, PCR, or Western blot studies
• Paclitaxel neuropathy and postbiotic projects
• Any claim of a mechanism without the assay to measure it

Final ranking for you

1. Famotidine vs pantoprazole in restraint-stress gastric injury
   Best rat project for clinical relevance and external impression.
2. Metformin chronopharmacology with OGTT
   Best low-cost, clean, modern project with reliable numerical data.
3. Propranolol in restraint stress, gastric injury, and behavioural change
   Most novel-looking integrated pharmacology project, but only if you have behavioural apparatus.
4. Magnesium sulphate plus sodium valproate in PTZ seizures
   Strong CNS topic, but higher ethical and technical responsibility.

Option 1: Comparative evaluation of famotidine and pantoprazole against restraint-stress-induced gastric mucosal injury in Wistar rats.

Option 2: Chronopharmacological evaluation of metformin on oral glucose tolerance in Wistar rats.

Unique rat project topics with ratings

Top 5 distinctive choices

1. Best overall: ondansetron and gastrointestinal motility

“Evaluation of low-dose ondansetron on gastric emptying and intestinal transit in Wistar rats.”

• Not a routine analgesic, antidiabetic, or anti-ulcer study.
• Connects antiemetic pharmacology with the clinically relevant adverse effect of constipation or slowed gut movement.
• Uses affordable measurable endpoints.
• Gives good viva discussion on serotonin receptors, enteric nervous system, upper versus lower gastrointestinal motility, and drug adverse effects.

• Percentage gastric emptying
• Percentage intestinal transit
• Stool number and fecal water content, if you extend the study

---

2. Best integrated project: stress, glucose and gastric injury

“Evaluation of propranolol as a modulator of restraint stress-induced hyperglycaemia and gastric mucosal injury in Wistar rats.”

• Tests one drug across two linked outcomes of stress physiology.
• Strong pharmacology story: sympathetic activation, catecholamines, blood glucose, mucosal circulation, and β-adrenergic blockade.
• Uses inexpensive drugs and basic measurements.

---

3. Most unusual low-cost idea: furosemide chronopharmacology

“Chronopharmacological evaluation of furosemide-induced diuresis in Wistar rats.”

• Simple, objective data.
• Not overused in student projects.
• You can discuss circadian biology, renal physiology, pharmacodynamics, and rational timing of diuretic therapy.
• Does not require biochemical kits if you only measure urine volume, onset, and duration.

---

4. Best autonomic-pharmacology idea

“Comparative evaluation of cetirizine and levocetirizine on locomotor activity, motor coordination and exploratory behaviour in Wistar rats.”

• Clear comparison of commonly used second-generation antihistamines.
• Practical relevance: residual sedation and psychomotor impairment.
• Low cost and safer than ulcer or seizure models.
• Reliable data if actophotometer and rotarod are available.

---

5. Best constipation project

“Comparative evaluation of lactulose and magnesium sulphate in loperamide-induced constipation in Wistar rats.”

• Strong clinical relevance.
• More useful than simply proving a laxative works.
• Easy endpoints: fecal count, fecal water, charcoal-meal transit.
• Lets you compare osmotic laxatives with different practical pharmacology.

My final recommendation

1. Low-dose ondansetron on gastric emptying and intestinal transit in Wistar rats
2. Propranolol in restraint stress-induced hyperglycaemia and gastric mucosal injury
3. Chronopharmacology of furosemide-induced diuresis

“Chronopharmacological evaluation of furosemide-induced diuresis in Wistar rats.”

“Evaluation of low-dose ondansetron on gastric emptying and intestinal transit in Wistar rats.”

“No study was identified during the literature search that evaluated this exact drug, dose, model, and outcome combination.”

Best 5 unique choices

1. Ondansetron-induced GI motility alteration

“Evaluation of ondansetron-induced alteration in gastrointestinal motility and its reversal by a prokinetic agent in Wistar rats.”

• Looks clinically relevant because constipation is a practical adverse effect of 5-HT3 antagonists.
• Covers both adverse-effect pharmacology and rescue therapy.
• Strong viva discussion: serotonin receptors, enteric nervous system, gastric emptying, intestinal transit, antiemetic adverse effects.
• Does not require ELISA, PCR, histopathology, or expensive kits.

---

2. Iron preparation-associated constipation

“Comparative evaluation of oral iron preparations for constipation-like effects and intestinal transit in Wistar rats.”

• Iron-associated gastrointestinal intolerance is clinically important.
• Compares safety, rather than only testing efficacy.
• Different from routine pharmacology projects.
• Cheap if standard iron salts are available.

• Ferrous sulphate
• Ferrous fumarate
• A better-tolerated preparation available locally

---

3. Isoniazid plus pyridoxine neurobehavioural safety

“Effect of pyridoxine supplementation on isoniazid-induced neurobehavioural toxicity in Wistar rats.”

• Directly connected to a real clinical preventive practice.
• Allows a high-quality pharmacology discussion: vitamin B6, GABA synthesis, isoniazid toxicity, peripheral neuropathy and seizure risk.
• Better than simply testing anticonvulsant activity.

---

4. Furosemide chronopharmacology

“Chronopharmacological comparison of furosemide-induced diuresis in Wistar rats.”

• Objective, clean numerical data.
• Very low reagent cost.
• Distinct topic that few student projects select.
• You can discuss circadian rhythm, renal physiology, diuretic pharmacodynamics, and rational dosing time.

---

5. Caffeine withdrawal: brain-gut pharmacology

“Effect of short-term caffeine withdrawal on anxiety-like behaviour, locomotor activity, and gastrointestinal transit in Wistar rats.”

• Connects CNS and gastrointestinal pharmacology.
• Caffeine is inexpensive and familiar.
• Lets you explain adenosine receptors, tolerance, withdrawal, anxiety, and gut motility.
• More interesting than only measuring locomotor activity.

My honest final recommendation

“Evaluation of ondansetron-induced alteration in gastrointestinal motility and its reversal by a prokinetic agent in Wistar rats.”

“Chronopharmacological comparison of furosemide-induced diuresis in Wistar rats.”

“Effect of pyridoxine supplementation on isoniazid-induced neurobehavioural toxicity in Wistar rats.”

“No study was identified evaluating this exact drug, dose schedule, rat model, and combined endpoint set during the structured literature search.”

A less commonly studied disease model + a clinically relevant drug problem + a precise low-cost endpoint set.

Unique disease-based rat topics

Top 3 best choices

1. NSAID-induced small-intestinal enteropathy

“Evaluation of famotidine versus pantoprazole on indomethacin-induced small-intestinal enteropathy and intestinal transit in Wistar rats.”

• Most student projects study only gastric ulcers.
• This focuses on the relatively neglected small-intestinal injury caused by NSAIDs.
• You can explain that reducing acid does not automatically prove protection in the small intestine.
• It combines adverse-drug-reaction pharmacology, gastrointestinal pharmacology, and intestinal motility.
• No costly molecular assays are required if you use gross lesion scoring and transit testing.

---

2. Oral iron-associated constipation-like bowel dysfunction

“Comparative evaluation of ferrous sulphate and ferrous fumarate on constipation-like bowel dysfunction and intestinal transit in Wistar rats.”

• Oral iron causes clinically important gastrointestinal intolerance.
• This evaluates drug safety and tolerability, not merely efficacy.
• It is different from routine anti-ulcer, antidiabetic, analgesic, and anti-inflammatory projects.
• Drugs and endpoints are low-cost.
• You can discuss formulation choice, adherence, adverse effects, and intestinal motility.

---

3. Ondansetron-associated delayed GI transit

“Evaluation of a prokinetic approach against ondansetron-associated delayed gastric emptying and intestinal transit in Wistar rats.”

• Ondansetron is widely used as an antiemetic, while constipation and slowed bowel movement are clinically relevant adverse effects.
• It has a good pharmacological story: 5-HT3 antagonism, enteric nervous system, motility, adverse-effect management.
• It provides two objective outcomes: gastric emptying and intestinal transit.
• It is more distinctive than a standard laxative study.

My strongest recommendation

“Comparative evaluation of famotidine and pantoprazole on indomethacin-induced small-intestinal enteropathy and intestinal transit in Wistar rats.”

Simple low-cost outcomes

1. Body-weight change
2. Small-intestinal lesion number and lesion score
3. Intestinal transit using charcoal meal
4. Fecal occult blood, only if low-cost kits are available
5. Gross photograph documentation of intestinal lesions

Important caution

“A structured literature search will assess whether the selected intervention has been evaluated in this exact rat model, with this dose schedule and these combined gastrointestinal outcome measures. The proposed study addresses this specific evidence gap.”

“No published study was identified for this exact drug, dose, disease model, and endpoint combination after a structured PubMed and Scopus search.”

Unique and relatively rare disease-syndrome topics in rats

Top 3 that will impress an external

1. NSAID-induced small-intestinal enteropathy

“Comparative evaluation of selected gastroprotective strategies in indomethacin-induced small-intestinal enteropathy and altered intestinal transit in Wistar rats.”

• Small-intestinal lesion number and severity score
• Intestinal length
• Body-weight change
• Charcoal-meal intestinal transit
• Gross photographs of lesions

---

2. Functional dyspepsia-like delayed gastric emptying

“Evaluation of a repurposed prokinetic strategy in restraint-stress-induced functional dyspepsia-like delayed gastric emptying in Wistar rats.”

• Percentage gastric emptying
• Intestinal transit
• Food intake
• Body-weight change
• Anxiety-like behaviour only if your department has open-field or elevated-plus-maze apparatus

---

3. Cyclophosphamide-induced haemorrhagic cystitis

“Evaluation of [selected low-cost repurposed drug] against cyclophosphamide-induced haemorrhagic cystitis in Wistar rats.”

• Bladder weight
• Urine colour or haematuria score
• Gross bladder lesion score
• Water intake and urine output
• Body-weight change

---

Best final pick for you

Select this if you want maximum uniqueness within ₹10k:

“Evaluation of a repurposed gastroprotective strategy in indomethacin-induced small-intestinal enteropathy and altered intestinal transit in Wistar rats.”

• gastric ulcer models
• carrageenan paw oedema
• diabetes models
• analgesic screening
• routine constipation models

What not to select despite sounding rare

• Fabry disease
• Pompe disease
• Wilson disease
• Huntington disease
• Duchenne muscular dystrophy
• Spinal muscular atrophy
• Pulmonary arterial hypertension
• Pulmonary fibrosis
• Chronic kidney disease with vascular calcification
• Endometriosis
• Parkinsonism with molecular markers

How to make the rare topic scientifically strong

• Random allocation of rats to groups
• Blinded lesion and behavioural scoring
• A standard comparator drug
• One primary endpoint, decided before starting
• One safety or functional endpoint
• Clear humane endpoints and IAEC approval

Rare and unique rat disease-topic ideas

Best rare topic to impress your external

1. Tardive dyskinesia-like syndrome

“Evaluation of [selected repurposed drug] in haloperidol-induced tardive dyskinesia-like oro-facial dyskinesia in Wistar rats.”

Why it is strong

• Tardive dyskinesia is a serious, often persistent adverse effect of chronic antipsychotic therapy.
• It is much more unusual than routine analgesic, ulcer, antidiabetic, or anti-inflammatory studies.
• It provides an excellent viva discussion on dopamine receptor blockade, dopamine receptor supersensitivity, oxidative stress hypothesis, abnormal involuntary movements, and adverse drug reaction management.
• You can measure visible behavioural outcomes without ELISA, PCR, or histology.
• It is a proper neuropharmacology and pharmacovigilance project.

Practical outcomes

• Frequency of vacuous chewing movements
• Tongue protrusions
• Facial jerking or chewing episodes
• Locomotor activity
• Rotarod performance, to separate dyskinesia from general motor impairment

Second-best rare topic

Cyclophosphamide-induced haemorrhagic cystitis

“Evaluation of a low-cost uroprotective intervention against cyclophosphamide-induced haemorrhagic cystitis in Wistar rats.”

Third-best rare topic

Isoniazid-associated neurotoxicity

“Effect of pyridoxine dosing schedule on isoniazid-induced peripheral neurobehavioural toxicity in Wistar rats.”

Best shortlist for your guide

1. Haloperidol-induced tardive dyskinesia-like oro-facial dyskinesia in Wistar rats
   Best for external impression and neuropharmacology viva.
2. Cyclophosphamide-induced haemorrhagic cystitis in Wistar rats
   Best rare supportive-care topic, but needs cytotoxic-drug safety capability.
3. Isoniazid-induced peripheral neurobehavioural toxicity in Wistar rats
   Best tuberculosis-drug-safety project.
4. Indomethacin-induced small-intestinal enteropathy in Wistar rats
   Best gastrointestinal adverse-drug-reaction project.
5. Stress-induced functional dyspepsia-like delayed gastric emptying in Wistar rats
   Best brain-gut pharmacology project.

My final recommendation

“Evaluation of [test drug] in haloperidol-induced tardive dyskinesia-like oro-facial dyskinesia in Wistar rats.”

“No study was identified evaluating this exact intervention, dose schedule, haloperidol exposure protocol, and behavioural outcome panel in Wistar rats.”

• Scientific relevance and novelty
• Strength of pharmacology concept
• Clinical relevance
• Feasibility in an M.Pharm lab
• Suitability for approximately ₹10,000
• Quality of viva discussion

Ranking of your topics

Best topic to impress an external

1. NSAID-induced small-intestinal enteropathy

“Comparative evaluation of selected protective strategies in indomethacin-induced small-intestinal enteropathy and altered intestinal transit in Wistar rats.”

Why it is the strongest

• Most students choose an NSAID gastric ulcer model. Your project addresses the less-discussed small-intestine injury.
• It demonstrates understanding of adverse drug reactions, gastrointestinal pharmacology, intestinal motility, and limitations of routine gastroprotection.
• It gives you excellent viva points:
  • Why gastric protection may not equal intestinal protection
  • NSAID-related injury beyond the stomach
  • Importance of intestinal transit as a functional endpoint
  • Drug safety rather than only drug efficacy
• It can be assessed at low cost with lesion scoring, intestinal length, body weight, charcoal transit, and gross photographs.

---

Best if you want a rare disease-like syndrome

2. Functional dyspepsia-like delayed gastric emptying

“Evaluation of a repurposed prokinetic drug in restraint-stress-induced functional dyspepsia-like delayed gastric emptying in Wistar rats.”

• Stress physiology
• Brain-gut axis
• Functional dyspepsia
• Gastric dysmotility
• Rational repurposing of a prokinetic drug

• Percentage gastric emptying
• Charcoal-meal intestinal transit
• Food intake
• Body weight
• Behavioural observation if open-field apparatus is available

---

Best rare neuropharmacology topic

3. Tardive dyskinesia-like syndrome

“Evaluation of [selected repurposed drug] in haloperidol-induced tardive dyskinesia-like oro-facial dyskinesia in Wistar rats.”

• Your guide has already performed the haloperidol model.
• You can maintain the chronic dosing schedule.
• You have access to an actophotometer or rotarod.
• You can score vacuous chewing movements in a blinded manner.

---

My final selection order for you

If your priority is highest external impression:

1. NSAID-induced small-intestinal enteropathy - 9.3/10
2. Functional dyspepsia-like delayed gastric emptying - 9.1/10
3. Haloperidol-induced tardive dyskinesia-like syndrome - 9.0/10

If your priority is low cost and successful completion:

1. Metformin chronopharmacology with OGTT - 8.7/10
2. Oral iron-associated bowel dysfunction - 8.8/10
3. Metformin-paracetamol low-dose combination - 8.6/10

Avoid under ₹10k

• Diabetic neuropathy plus ferroptosis
• Postbiotic therapy in chemotherapy neuropathy
• Cyclophosphamide cystitis unless the institution provides cytotoxic-drug facilities

My one best recommendation

“Evaluation of a repurposed prokinetic drug in restraint-stress-induced functional dyspepsia-like delayed gastric emptying in Wistar rats.”

“No published study was identified that evaluated this exact intervention, dose schedule, restraint-stress model, and combined gastric-emptying and intestinal-transit outcomes.”

Ratings of the four topics

---

1. Best choice: Zebrafish larval drug screen for Dravet syndrome

Rating: 9.5/10 for external impression

Better title

“Phenotype-guided screening of repurposed small molecules in a zebrafish larval model of Dravet syndrome.”

“Evaluation of selected repurposed small molecules in a scn1lab-deficient zebrafish larval model of Dravet syndrome.”

Why it will impress an external

• Dravet syndrome is a severe developmental and epileptic encephalopathy, not a routine seizure model.
• It uses a modern, ethical, high-throughput vertebrate model.
• It involves drug repurposing, rare-disease pharmacology, larval behaviour, and seizure phenotype assessment.
• Zebrafish research can generate several outcomes: locomotor hyperactivity, seizure-like behaviour, survival, morphology, and toxicity.
• It provides excellent viva points about SCN1A-related disease, sodium-channel dysfunction, translational screening, and the 3Rs.

Main risk

• Zebrafish breeding and larval-maintenance system
• A validated scn1lab mutant or equivalent Dravet line
• Stereo microscope and behavioural recording setup
• Personnel trained in zebrafish husbandry and scoring

---

2. Alternating hemiplegia of childhood in C. elegans

Rating: 9.1/10 for external impression

Better title

“Pharmacological evaluation of selected repurposed small molecules in a Caenorhabditis elegans model of ATP1A3-related alternating hemiplegia of childhood.”

Why it is strong

• Alternating hemiplegia of childhood is a very rare ATP1A3-related neurodevelopmental disorder.
• C. elegans is a low-cost model with good suitability for early-stage drug screening.
• It demonstrates knowledge of rare disease, genetic disease modelling, repurposing, and simple organism pharmacology.
• It is less expensive and easier to scale than rat or zebrafish work.

Major correction

“No study was identified evaluating this defined panel of repurposed small molecules in the selected ATP1A3-variant C. elegans model using the specified behavioural and neuromuscular outcome panel.”

Main risk

---

3. Statin repurposing for an ultra-rare glycosylation disorder

Current rating: 8.8/10 potential, but only 5/10 as currently written

“Repurposing a statin for an ultra-rare glycosylation disorder.”

• Which congenital disorder of glycosylation?
• Which gene defect?
• Which statin?
• Why should inhibition of HMG-CoA reductase help that condition?
• What model will be used?
• What phenotype will improve?
• How will glycosylation or disease phenotype be measured?

How to make it strong

“Evaluation of [specific statin] in a [specific gene]-deficient C. elegans or zebrafish model of [named congenital disorder of glycosylation].”

1. A suitable disease model exists in your department or collaborator lab.
2. The statin has a published mechanistic rationale.
3. You have a measurable phenotype: locomotion, survival, developmental delay, morphology, mitochondrial function, or other validated readout.

Verdict

---

4. “Sensitised drug screen in a particular C. elegans model”

Current rating: Not rateable

Disease or gene + sensitising condition + test-drug library + measurable phenotype

“Sensitised screening of repurposed drugs in a C. elegans model of [named rare disease] using [specific stressor or genetic sensitisation] and locomotor recovery as the primary endpoint.”

---

Final ranking for you

Choose this if your college has zebrafish facilities

1. Dravet syndrome zebrafish larval drug screen

Choose this if your college has a C. elegans laboratory but no zebrafish facility

2. ATP1A3-related alternating hemiplegia of childhood in C. elegans

Avoid selecting now

3. Statin in rare glycosylation disorder

My recommendation

“Phenotype-guided screening of selected repurposed small molecules in a scn1lab-deficient zebrafish larval model of Dravet syndrome.”

Ratings for external-examiner impression

Best choice: Letrozole-induced PCOS in rats

Refined title

“Evaluation of [selected low-cost intervention] on ovarian morphology and metabolic dysfunction in letrozole-induced polycystic ovary syndrome in female Wistar rats.”

Why it will impress the external

• PCOS is clinically important and combines reproductive endocrinology, metabolic pharmacology, and histopathology.
• The letrozole rat model is well known and defensible. It can reproduce hyperandrogenic and ovarian features, while metabolic outcomes require proper model design and measurement.
• You can present multiple integrated outcomes:
  • Estrous-cycle irregularity by vaginal cytology
  • Ovarian weight and morphology
  • Ovarian histology, if your college provides it
  • Body-weight change
  • Fasting glucose and oral glucose-tolerance test
  • Optional lipid profile only if funding permits
• It is easier to explain and defend than an exploratory areca-nut neurotoxicity model.

Main limitation

1. A scientifically justified, defined test intervention
2. A focused question
3. Proper metabolic and ovarian outcomes
4. Good study design

Best low-cost intervention options

• Myo-inositol: clinically relevant but confirm cost
• Metformin as positive-control or comparator: useful, but not your novel test drug
• Vitamin D, only if you can justify baseline deficiency or a clear mechanistic question
• N-acetylcysteine, clinically relevant antioxidant/insulin-sensitising rationale, but check cost
• Pyridoxine or magnesium, lower-cost but need a strong literature-based reason

---

Why Topic 1 is weaker despite sounding unique

Your proposed topic

“Areca nut-induced neurobehavioural changes and oxidative stress in mice: evaluation of a protective intervention.”

Strengths

• Areca nut use is regionally and clinically relevant.
• It is less commonly selected than PCOS.
• It can produce an interesting pharmacovigilance or toxicology story.

Problems an external may ask

1. Which areca preparation? Raw nut, extract, arecoline, pan masala-like mixture?
2. What human exposure does your dose represent?
3. Which neurobehavioural domain? Anxiety, cognition, locomotion, dependence, depression-like behaviour?
4. What proves oxidative stress? You need at least validated biochemical markers such as MDA, reduced glutathione, SOD, or catalase.
5. Which protective intervention and why?
6. Is it a validated mouse model?

---

Final decision

Choose Topic 2 if you want:

• Better marks
• Easier viva
• Strong disease relevance
• Clear and measurable endpoints
• A more reliable project outcome

Choose Topic 1 only if:

• Your guide has already worked with areca-nut or arecoline animal exposure
• You have access to oxidative-stress assays
• You can specify the exact exposure substance and neurobehavioural outcomes

Best viva statement for Topic 2

“PCOS is not solely an ovarian disorder. It is a reproductive-metabolic syndrome characterised by ovarian dysfunction and insulin-resistance-related metabolic abnormalities. This study evaluates whether a defined low-cost intervention improves both ovarian morphology and metabolic dysfunction in a validated letrozole-induced rat model, with metformin as the pharmacological comparator.”

1. C. elegans model of alternating hemiplegia of childhood
2. Statin repurposing for an ultra-rare congenital disorder of glycosylation
3. Zebrafish larval screen for Dravet syndrome
4. Sensitised drug screen in a specific C. elegans model
5. Areca-nut-induced neurobehavioural toxicity in mice
6. Letrozole-induced PCOS in rats

Overall ranking to impress an external examiner

My clear recommendation

Choose Topic 1 overall, only if the laboratory already has zebrafish infrastructure:

“Phenotype-guided evaluation of selected repurposed small molecules in a scn1lab-deficient zebrafish larval model of Dravet syndrome.”

• A severe rare paediatric disease
• A disease-relevant genetic model
• Drug repurposing
• Modern larval behavioural screening
• A 3Rs-aligned model
• A direct translational rationale

Choose Topic 2 if you do not have zebrafish:

“Pharmacological evaluation of selected repurposed small molecules in a Caenorhabditis elegans model of ATP1A3-related alternating hemiplegia of childhood.”

Choose Topic 3 if your department requires rats:

“Evaluation of [defined low-cost intervention] on ovarian morphology and metabolic dysfunction in letrozole-induced polycystic ovary syndrome in female Wistar rats.”

• Vaginal cytology
• Ovarian morphology or histology
• Body weight
• Fasting glucose and OGTT
• Metformin as standard comparator

Final decision rule

• Zebrafish facility + scn1lab line available: Choose Dravet zebrafish - 9.5/10
• C. elegans facility + validated ATP1A3 model available: Choose AHC worm model - 9.2/10
• Only standard rat laboratory available: Choose letrozole-PCOS rat project - 8.7/10
• No validated model or specialised facility: Do not select statin-glycosylation or vague sensitised-screen topics.

1. Zebrafish Dravet syndrome drug screen
2. C. elegans model of alternating hemiplegia of childhood
3. Statin repurposing in a congenital disorder of glycosylation
4. Sensitised drug screen in a C. elegans disease model
5. Areca-nut-induced neurobehavioural toxicity in mice
6. Letrozole-induced PCOS in rats

Direct comparison

Best ranking by criterion

Best for novelty

1. Statin in a defined congenital disorder of glycosylation
2. AHC in C. elegans
3. Dravet syndrome zebrafish screen
4. Sensitised C. elegans screen, only after defining the disease
5. Areca neurotoxicity
6. PCOS rat model

Best for feasibility under ₹10,000

1. AHC in C. elegans, if strain and worm facility exist
2. Sensitised C. elegans screen, only if your lab already has the model
3. Dravet zebrafish, only if mutant line and zebrafish facility exist
4. Letrozole-PCOS rats, if animal house and histology support are provided
5. Areca neurotoxicity in mice
6. Statin-glycosylation disorder, unless it is a fully supported collaborative project

Best for external-examiner impression

1. Dravet syndrome zebrafish screen - 9.5/10
2. AHC C. elegans model - 9.2/10
3. Letrozole-PCOS rat model - 8.7/10
4. Statin-glycosylation topic - 8.5/10 potential, but only 5/10 if vague
5. Areca neurotoxicity model - 7.8/10
6. Unspecified sensitised screen - not suitable until properly defined

My practical recommendation

If your college has a validated C. elegans disease strain and a guide experienced in worm work:

“Pharmacological evaluation of selected repurposed small molecules in a Caenorhabditis elegans model of ATP1A3-related alternating hemiplegia of childhood.”

If your college already has zebrafish, a scn1lab mutant line, behavioural recording, and trained staff:

“Phenotype-guided evaluation of selected repurposed small molecules in a scn1lab-deficient zebrafish larval model of Dravet syndrome.”

If you have only a standard animal house with rats:

“Evaluation of [defined low-cost intervention] on ovarian morphology and metabolic dysfunction in letrozole-induced PCOS in female Wistar rats.”

Do not select these without clarification

Statin for glycosylation disorder

• The exact disorder and causative gene
• The selected statin
• Why a statin is mechanistically justified
• The available validated model
• The measurable disease phenotype

Sensitised C. elegans drug screen

Disease gene + worm strain + sensitising condition + drug panel + primary phenotype

Final answer

1. ATP1A3-related alternating hemiplegia of childhood in C. elegans
2. Lafora disease in epm2a-deficient zebrafish larvae
3. N-acetylcysteine intervention in letrozole-induced PCOS in Wistar rats

---

1. C. elegans model of Alternating Hemiplegia of Childhood

Final title

Key feasibility requirement

Experimental plan

Step 1: Select strains

• Wild-type control strain
• Validated AHC mutant strain, for example a heterozygous eat-6 knock-in corresponding to an ATP1A3 disease variant
• If available, more than one mutant allele can be included, but for an M.Pharm project one robust mutant allele is enough

Step 2: Synchronise worms

• Maintain worms according to the host laboratory’s standard worm-culture SOP.
• Obtain age-synchronised animals.
• Use the same developmental stage for every group, usually young adults or the stage used by the source laboratory.
• Confirm normal bacterial food source, temperature, and plate conditions across groups.

Step 3: Select repurposed compounds

• Neuronal excitability
• Ion-homeostasis modulation
• Calcium handling
• Neuromuscular transmission
• Existing human safety information

1. Wild-type plus vehicle
2. Mutant plus vehicle
3. Mutant plus each test compound
4. Optional wild-type plus the most promising compound, to identify non-specific toxicity

Step 4: Tolerability and concentration-range study

• Test a small concentration range of each compound in wild-type worms.
• Observe survival, movement, developmental progression, and visible toxicity.
• Select concentrations that do not cause paralysis, developmental delay, marked lethality, or severe locomotor suppression.

Step 5: Primary phenotype evaluation

• Locomotor activity
• Thrashing/swimming behaviour
• Crawling speed
• Neuromuscular-junction functional assay
• Response to a standard cholinergic or neuromuscular challenge, only if already validated locally

Step 6: Secondary outcomes

• Survival
• Developmental stage
• Body length or growth proxy
• Reproductive capacity, if feasible
• General movement in wild-type worms
• Sleep/arousal-like phenotype only if your lab has a validated assay

Step 7: Blinding and analysis

• Randomize treatment plates.
• Code the plates so the scorer does not know the genotype or drug.
• Perform at least 2 to 3 independent biological repeats.
• Predefine the primary endpoint before data collection.
• Compare genotype, treatment, and genotype-treatment interaction.

Expected outcome

• Improve mutant locomotor or neuromuscular phenotype
• Not reduce wild-type movement
• Not delay development
• Not increase mortality

Strong viva statement

“The study uses a genetically defined ATP1A3-equivalent model to identify whether selected clinically used small molecules can rescue a quantifiable neuromuscular phenotype. We distinguish genuine phenotypic rescue from non-specific sedation, developmental delay, or toxicity.”

---

2. Zebrafish larval screen for Lafora disease

Final title

Important correction

Key feasibility requirement

• A zebrafish facility
• An existing epm2a-deficient zebrafish line
• Embryo collection and larval rearing support
• Stereo microscope
• Behavioural tracking system or video-recording system
• Guide trained in zebrafish larval screening

Experimental plan

Step 1: Prepare and identify larvae

• Breed heterozygous or mutant adult fish according to local fish-facility SOP.
• Collect embryos and maintain them in approved embryo medium.
• Stage larvae by hours or days post fertilisation.
• Identify mutant and control larvae by facility-approved genotype or breeding strategy.
• Use larvae at the same developmental stage for all experiments.

Step 2: Select a focused drug panel

• Neuronal hyperexcitability
• Glucose/glycogen-related biology
• Autophagy-lysosomal pathways
• Oxidative-stress modulation
• Existing CNS safety profile

1. Wild-type plus vehicle
2. Lafora-model larvae plus vehicle
3. Lafora-model larvae plus test drug 1
4. Lafora-model larvae plus test drug 2
5. Lafora-model larvae plus test drug 3
6. Optional reference compound, only if scientifically justified

Step 3: Determine maximum tolerated concentration

• Expose normal larvae to a concentration range of each candidate.
• Observe mortality, heart rate if the facility routinely measures it, gross morphology, swimming ability, and developmental delay.
• Select a dose that is tolerated and does not suppress normal locomotion.

Step 4: Drug exposure

• Expose larvae to vehicle or test compound in a coded and randomized manner.
• Keep solvent concentration identical across all groups.
• Maintain identical light-dark cycle, temperature, and medium conditions.
• Use the exposure window already validated by the local facility.

Step 5: Behavioural assessment

• Total distance moved
• Average swim velocity
• High-velocity burst events
• Seizure-like swimming episodes
• Immobility duration
• Response during light-dark transition, if used by your facility

Step 6: Confirm hits

• Repeat in at least two independent larval clutches.
• Confirm that survival and morphology remain normal.
• If available, perform local-field-potential recording or another electrophysiological method to verify reduced seizure-like activity.

Step 7: Analysis

• Treat individual larvae as experimental units only if exposure and tracking are independent.
• Include clutch as a possible biological variable.
• Compare mutant vehicle versus mutant treatment first.
• Also compare treated wild-type larvae to assess toxicity/sedation.
• Report mortality and excluded tracking files.

Expected outcome

• Reduce mutant hyperactivity or seizure-like burst events
• Preserve normal larval survival and morphology
• Not suppress locomotion in wild-type larvae
• Show similar benefit in independent repeat experiments

Strong viva statement

“The model is used as a phenotype-guided first-pass screen. A compound is considered a genuine pharmacological hit only when it improves the mutant behavioural phenotype without causing sedation, developmental toxicity, or mortality.”

---

3. Letrozole-induced PCOS in female Wistar rats

Final title

Why this is the most practical topic

• Standard animal-house project
• Clear disease relevance
• Easily understood in viva
• Multiple low-cost outcomes
• Strong reproductive plus metabolic pharmacology story

Suggested experimental groups

Detailed procedure

Phase 1: Animal selection and acclimatisation

• Use adult female Wistar rats with regular estrous cycles.
• Acclimatise animals under standard laboratory conditions.
• Record baseline body weight.
• Assess estrous cyclicity by vaginal cytology before randomisation.
• Include animals showing regular cycling according to the local validated method.

Phase 2: Randomisation

• Randomly allocate eligible animals to study groups.
• Use a coding method so the person examining vaginal smears and ovarian samples is blinded to group allocation.
• Record all exclusions before starting treatment.

Phase 3: PCOS induction

• Induce PCOS using your IAEC-approved letrozole protocol.
• Letrozole is commonly administered orally in a suitable vehicle such as carboxymethylcellulose.
• A published protocol used letrozole 1 mg/kg/day orally with standard chow or high-fat diet, but your guide must select the final regimen based on the local model validation and ethics approval. The 2025 model study illustrates this type of approach.
• Monitor body weight and general health regularly.

Phase 4: Confirm PCOS-like phenotype

• Persistent estrous-cycle irregularity
• Increased body weight or altered weight gain
• Ovarian morphological changes, if feasible
• Fasting glucose or impaired oral glucose tolerance, depending on the model

Phase 5: Intervention treatment

• Administer N-acetylcysteine using the final guide-approved route, dose, and duration.
• Administer metformin reference treatment to the standard group if included.
• Give vehicle to control groups on the same schedule.
• Monitor body weight, feed intake if feasible, and overt toxicity.

Phase 6: Estrous-cycle assessment

• Collect vaginal smears at the same time each day.
• Stain and identify predominant cell populations using your departmental SOP.
• Record the proportion of time spent in each estrous phase.
• Persistent diestrus or irregular cycles support PCOS-like reproductive dysfunction.

Phase 7: Metabolic assessment

Fasting blood glucose

• Conduct only according to animal ethics approved fasting duration.
• Measure fasting glucose using validated glucometer strips or laboratory estimation.

Oral glucose tolerance test

• Record fasting baseline glucose.
• Administer the approved oral glucose load.
• Measure blood glucose at pre-specified time points in the approved protocol.
• Calculate glucose area under the curve, which is more informative than reporting a single glucose reading.

Phase 8: Ovarian assessment

1. Collect ovaries
2. Record ovarian weight
3. Note gross appearance
4. If histology is available:
   • Fix tissue using local pathology SOP
   • Prepare H&E-stained sections
   • Blind the assessor
   • Count or score:
     • Cystic follicles
     • Corpora lutea
     • Follicular development
     • Stromal thickening or hyperplasia, if applicable

Phase 9: Statistical analysis

• Glucose AUC, if metabolic dysfunction is your main focus, or
• Blinded ovarian histology score, if pathology support is available

• Estrous-cycle regularity
• Body-weight change
• Fasting glucose
• Ovarian weight
• Cystic follicle count
• Corpus luteum count

Expected outcome

• Irregular estrous cyclicity
• Ovarian cystic changes
• Reduced corpora lutea
• Increased body weight or metabolic dysfunction
• Impaired glucose tolerance

Strong viva statement

“This project evaluates PCOS as a reproductive-metabolic syndrome rather than only an ovarian condition. We assess estrous cyclicity, ovarian morphology, fasting glucose, and oral glucose tolerance, while using metformin as a pharmacological reference where feasible.”

Best choice by infrastructure

• C. elegans facility and validated AHC strain available: choose AHC worm model
• Zebrafish facility and epm2a mutant line available: choose Lafora disease model
• Only regular pharmacology animal house and budget around ₹10k: choose letrozole-PCOS rat study

1. AHC in C. elegans
   • Primary 2026 eat-6/ATP1A3 knock-in model paper
   • Recent AHC mouse-model and clinical-context papers
   • What phenotypes and screening endpoints support a drug-repurposing project
2. Lafora disease in epm2a-deficient zebrafish
   • Core zebrafish model and treatment-validation studies
   • Behavioural, seizure-like, molecular, and safety endpoints
   • Model limitations, especially early larval absence of Lafora bodies
3. Letrozole-induced PCOS in female Wistar rats
   • Recent validation papers comparing letrozole alone versus letrozole plus high-fat diet
   • Evidence for reproductive and metabolic endpoints
   • How to select a defensible, low-cost design for an NAC project

“No published study was identified that tested this specific intervention, dose strategy, mechanism, disease model, and sex-stratified design as of the protocol search date.”

Ranked M.Pharm pharmacology animal-study topics

Best 3 choices for a typical M.Pharm laboratory

1. Diabetic neuropathy plus ferroptosis

• Reliable, affordable animal model.
• Multiple pharmacological endpoints.
• Clear positive control: pregabalin or duloxetine.
• Can generate behavioural, biochemical, molecular and histopathology data.
• Good publication potential if you include both sexes and a predefined ferroptosis panel.

2. Postbiotic therapy in chemotherapy-induced neuropathy

• Less crowded than generic antioxidant or herbal neuropathy projects.
• Strong mechanism: gut barrier to systemic inflammation to neuroinflammation to pain.
• Relevant to cancer supportive care.
• Avoid vague “probiotic” products. Use a defined, reproducible postbiotic or purified metabolite.

3. Opioid-induced bowel dysfunction combination therapy

• Clear clinical problem and straightforward endpoints.
• Lets you show that gastrointestinal protection does not reduce central analgesia.
• Offers a convincing combination-therapy publication angle.

How to make the work genuinely novel

1. Disease model: Use a clinically relevant model, not only an acute screening model.
2. Test drug: Prefer a standardised compound, repurposed drug, or well-characterised fraction.
3. Mechanism: Pre-specify one pathway, for example ferroptosis, NLRP3, gut permeability, or senescence.
4. Comparator: Include standard treatment such as pregabalin, duloxetine, diclofenac, or metformin as appropriate.
5. Sex: Include male and female animals if feasible, with sex-stratified analysis.
6. Functional endpoint: Include meaningful function, not only biochemical markers.
7. Safety: Add body weight, organ weight, serum biochemistry and target-organ histology.
8. Study quality: Randomisation, blinded outcome assessment, sample-size rationale, preregistered primary endpoint and ARRIVE 2.0 reporting.

Avoid these overdone M.Pharm topics

• “Antidiabetic activity of plant extract in STZ rats”
• “Anti-inflammatory activity using carrageenan paw oedema only”
• “Antioxidant activity of herbal formulation”
• “Antidepressant activity by forced-swim test only”
• “Hepatoprotective activity in paracetamol model”
• “Antiulcer activity in pylorus ligation”
• “Anticancer activity of a plant extract without target validation”
• “Nootropic activity using only scopolamine-induced amnesia”

Practical novelty-search protocol before finalising

("disease model") AND ("candidate drug/intervention") AND
("mechanism") AND (rat OR mouse OR animal)

("paclitaxel induced neuropathy") AND postbiotic AND NLRP3 AND rat

“A structured search was performed on [date] across PubMed, Scopus and Google Scholar. No study was identified evaluating [exact intervention] in [exact model] with simultaneous assessment of [functional endpoint] and [mechanistic biomarkers].”

My strongest recommendation

• IAEC/CPCSEA approval and animal-house access
• Animal cages, weighing balance, oral gavage needles, basic lab consumables
• Behavioural apparatus such as hot plate, actophotometer, elevated plus maze, or rotarod
• Faculty supervision and standard laboratory instruments

Best low-cost M.Pharm animal pharmacology topic

Recommended title

Why this is suitable

• Low cost: metformin and paracetamol are inexpensive generic medicines.
• Model is affordable: formalin test needs minimal reagents and gives two pain phases, early neurogenic pain and late inflammatory pain.
• Novelty is realistic: rather than claiming a new drug effect, test whether the combination, sex, and dosing time alter analgesic response.
• Pharmacology value: evaluates drug repurposing and combination therapy.
• Publication potential: better than a routine “plant extract has analgesic activity” study if randomisation, blinding and proper controls are used.
• No expensive biomarkers required: outcomes are observable pain behaviour and locomotor activity.

Simple design

1. Vehicle control
2. Paracetamol standard group
3. Metformin low-dose group
4. Metformin plus paracetamol low-dose combination
5. Combination administered in morning
6. Combination administered in evening

• Best option: male and female comparison
• Second option: morning versus evening dosing comparison

Main outcomes

• Formalin-induced paw-licking or paw-biting time in early and late phases
• Percentage inhibition of nociceptive behaviour
• Locomotor activity or rotarod assessment to show that reduced pain behaviour is not simply sedation or motor impairment
• Body-weight monitoring and gross toxicity observation

Approximate ₹10,000 budget

Other feasible ₹10k topics

1. Low-dose combination analgesia

• Very cheap and easy.
• But less novel than the metformin combination.
• Improve it by comparing male versus female animals.

2. Anti-inflammatory chronopharmacology

• Low cost if rats are available.
• Measures paw volume at fixed intervals.
• Add gastric-ulcer scoring only if facilities and IAEC approval permit.
• This is more feasible than advanced molecular projects but has moderate novelty.

3. Repurposing in acute inflammatory pain

• Cheapest option.
• Two complementary tests make the work stronger.
• Its gap is the low-dose combination and sex-stratified design, not the individual tests themselves.

4. CNS side-effect-aware analgesic screening

• Clinically relevant combination strategy.
• Include formalin test plus rotarod or actophotometer.
• Pregabalin can increase the cost slightly.

Best choice under ₹10k

“Sex-dependent antinociceptive interaction of low-dose metformin and paracetamol in formalin-induced persistent pain in Swiss albino mice.”

Important wording for your synopsis

“The available literature will be searched systematically to identify whether low-dose metformin-paracetamol combination therapy has been evaluated in formalin-induced persistent pain with sex-stratified behavioural and motor-safety outcomes. The proposed study addresses this specific evidence gap.”

Top low-cost topics, ranked

My top 5 recommendations

1. Metformin plus paracetamol in persistent pain

• Both medicines are cheap and easily available.
• Formalin gives early neurogenic and late inflammatory pain phases.
• A combination-treatment design is more useful than testing one common drug alone.
• You can add male-female comparison without expensive assays.
• Include an actophotometer or rotarod to exclude sedation/motor impairment.

---

2. Chronopharmacology of paracetamol

• Cheapest among good-quality topics.
• Same drug, same model, but different dosing time.
• Requires no ELISA, histology, PCR, or costly chemicals.
• Easy to explain in viva: biological rhythms may alter drug response.

---

3. Paracetamol plus caffeine in inflammatory pain

• Both drugs are low-cost.
• Clinically relevant because such combinations are used for pain.
• Easy endpoints.
• Better than a routine analgesic screening project because it evaluates both efficacy and motor safety.

---

4. Metformin plus diclofenac

• Adds anti-inflammatory and analgesic endpoints.
• Carrageenan paw oedema is simple if plethysmometer facilities are available.
• Metformin repurposing gives the project a modern pharmacology angle.

---

5. Diclofenac chronopharmacology with gastric safety

• Balances benefit and adverse effect, which is better pharmacology than efficacy alone.
• Uses readily available drugs and routine gastric ulcer scoring.
• Has a clinically relevant question: can dosing time improve efficacy-to-toxicity balance?

Lowest-cost options

1. Paracetamol morning versus evening study
2. Paracetamol-caffeine combination study
3. Metformin-paracetamol combination study
4. Paracetamol pretreatment-time study

How to increase the rating of any topic

• A standard-drug comparator
• One motor-safety test
• Random allocation of animals
• Blinded scoring of behavioural outcomes
• A defined primary endpoint
• Clear inclusion/exclusion criteria
• Body-weight and general-toxicity monitoring
• Male-female comparison or dosing-time comparison, but not both if the sample size becomes too small

Topics to avoid on a ₹10k budget

• Diabetic neuropathy with biochemical markers
• Parkinsonism, Alzheimer’s or stroke models
• Cancer models
• Microbiome, probiotics or postbiotics
• Ferroptosis, NLRP3, cytokines, ELISA, PCR, Western blot studies
• Nanoformulation projects
• Projects requiring histopathology if your institution charges separately
• Any herbal extract project without botanical authentication and standardisation

Best final selection

“Sex-dependent antinociceptive interaction of low-dose metformin and paracetamol in formalin-induced persistent pain in Swiss albino mice.”

**“Influence of administration time on paracetamol analgesia in formalin-induced inflammatory pain in Swiss albino mice.”**For a ₹10,000 maximum budget, the best choice from your list to impress an external examiner is:

Best final choice: Topic 3

Improved project title

“with assessment of pharmacodynamic interaction and motor safety.”

Why this is the best

• Looks more advanced than a simple analgesic screening study.
• Uses drug repurposing: metformin is an antidiabetic drug assessed as an adjunct analgesic.
• Uses a clinically meaningful question: can metformin allow a lower effective paracetamol dose?
• Can be completed in the ₹7,000 to ₹10,000 range if animal-house infrastructure is available.
• You can demonstrate a real pharmacology concept: additive, synergistic, or sub-additive interaction.
• The formalin model has two phases, allowing discussion of neurogenic versus inflammatory pain.
• Add rotarod or actophotometer testing, showing that reduced pain behaviour is not due to sedation or motor impairment.
• A 2025 mouse study reports that metformin reduces inflammatory nociception, so your project should focus on the specific low-dose metformin plus paracetamol interaction, rather than merely asking whether metformin is analgesic. See the 2025 metformin study.

Why externals will like it

“This is not a routine analgesic study. We assessed whether repurposed low-dose metformin can enhance paracetamol analgesia in persistent inflammatory pain, potentially reducing the required paracetamol dose and its dose-related toxicity. We also distinguished analgesia from motor impairment.”

---

Ranking of your five topics for an external examiner

Why not select the other options?

1. Diabetic neuropathy plus ferroptosis

2. Postbiotic treatment in chemotherapy-induced neuropathy

3. Chronopharmacology of paracetamol

4. Paracetamol plus caffeine

---

Proposed objectives for the selected topic

Final title for synopsis

Objectives

1. To evaluate the antinociceptive effect of low-dose metformin in the formalin test.
2. To evaluate the antinociceptive effect of a sub-effective or low dose of paracetamol.
3. To assess whether their combination produces additive or synergistic antinociception.
4. To compare effects in the early neurogenic phase and late inflammatory phase of the formalin test.
5. To assess locomotor coordination using rotarod or actophotometer.
6. To monitor body weight, gross toxicity signs and mortality during the study.

Minimal group plan

1. Vehicle control
2. Paracetamol low-dose
3. Metformin low-dose
4. Metformin plus paracetamol low-dose
5. Standard-dose paracetamol reference group

One important upgrade that impresses an external

• Additive
• Synergistic
• Antagonistic

What to tell the external in viva

“Metformin has emerging evidence of antinociceptive activity, but its ability to reduce the dose requirement of paracetamol in persistent inflammatory pain has not been adequately defined in our selected model. We therefore evaluated a low-dose combination, included a standard comparator, used separate neurogenic and inflammatory formalin phases, and checked motor safety to exclude false analgesic results caused by reduced movement.”

Best additional project ideas

Top three choices to impress an external

1. Metformin plus paracetamol

“Evaluation of the paracetamol-sparing effect of low-dose metformin in formalin-induced persistent inflammatory pain in Swiss albino mice.”

• Drug repurposing
• Rational combination pharmacology
• Dose-sparing potential
• A persistent inflammatory-pain model
• Motor-safety assessment
• Possibility of additive versus synergistic interaction analysis

2. Melatonin for NSAID gastric safety

“Evaluation of melatonin as a gastroprotective adjunct against diclofenac-induced gastric injury while preserving anti-inflammatory efficacy in rats.”

• Efficacy: reduction in inflammation
• Safety: prevention of NSAID-induced gastric damage

3. Chronopharmacology of diclofenac

“Chronopharmacological evaluation of diclofenac: influence of administration time on anti-inflammatory efficacy and acute gastric injury in rats.”

Which ideas are safest for your budget?

Very safe within ₹10k

• Paracetamol chronopharmacology
• Metformin-paracetamol combination
• Melatonin-paracetamol combination
• Paracetamol plus vitamin C
• Oral versus intraperitoneal paracetamol comparison
• Paracetamol-caffeine combination

Possible within ₹10k but confirm animal-house charges first

• Diclofenac gastric-safety studies
• Famotidine-diclofenac studies
• Melatonin-diclofenac gastroprotection
• Carrageenan plus ulcer-model projects

Avoid these, even though they sound advanced

• “Diabetic neuropathy with ferroptosis” without GPx4, SLC7A11, lipid-peroxidation, iron, or related assays
• “Postbiotic treatment in chemotherapy-induced neuropathy” without defined postbiotic characterisation or gut/inflammatory analysis
• “Antioxidant mechanism” without reliable biochemical measurements
• “Anti-inflammatory herbal extract” with only carrageenan paw oedema
• Any project that claims molecular mechanisms without molecular or biochemical evidence

How to make a low-cost topic look high quality

1. One strong research question
   • Example: “Can metformin reduce the paracetamol dose needed for inflammatory pain control?”
2. One primary outcome
   • Example: late-phase paw-licking time in the formalin test.
3. One safety outcome
   • Example: rotarod or actophotometer performance.
4. A standard comparator
   • Use standard-dose paracetamol or diclofenac where appropriate.
5. Good experimental design
   • Random allocation
   • Blinded scoring
   • Predefined inclusion/exclusion criteria
   • Appropriate statistical plan
   • No unnecessary animal groups

Final shortlist

1. Low-dose metformin as a paracetamol-sparing adjuvant in formalin-induced persistent inflammatory pain
2. Melatonin protection against diclofenac-induced gastric injury while retaining anti-inflammatory action
3. Chronopharmacological effect of diclofenac on inflammation and gastric injury

New low-cost topic ideas with ratings

Best 5 newer choices

1. Melatonin plus paracetamol in persistent pain

“Evaluation of the paracetamol-sparing effect of low-dose melatonin in formalin-induced persistent inflammatory pain in Swiss albino mice.”

• Rational multimodal analgesia approach.
• Melatonin allows discussion of pain modulation, sleep-pain interaction, oxidative stress, and chronopharmacology.
• Inexpensive drugs and simple animal model.
• Add rotarod/actophotometer to demonstrate that apparent analgesia is not due to sedation.

---

2. Famotidine versus pantoprazole in NSAID gastric injury

“Comparative evaluation of famotidine and pantoprazole against diclofenac-induced gastric injury in rats.”

• Clinically relevant safety-pharmacology topic.
• Includes a direct comparison of two common gastroprotective approaches.
• Easy outcomes: ulcer index, number and severity of lesions, gastric pH if the facility permits.
• Better than only testing “anti-ulcer activity” of one drug.

---

3. Pyridoxine plus paracetamol

“Evaluation of pyridoxine as a low-cost adjunct to paracetamol in formalin-induced inflammatory pain in mice.”

• Very low-cost.
• Vitamin B6 gives a plausible neuropharmacology discussion.
• More original than paracetamol-caffeine.
• Easy to complete with formalin testing and motor-safety testing.

---

4. Dosing interval, efficacy and toxicity of diclofenac

“Influence of dosing interval on the anti-inflammatory efficacy and acute gastric injury profile of diclofenac in rats.”

• Studies both efficacy and safety.
• Lets you discuss benefit-risk balance and rational dosing.
• Looks more advanced than a plain carrageenan paw-oedema project.

---

5. Metformin in visceral pain

“Evaluation of the antinociceptive and motor-safety profile of low-dose metformin in acetic-acid-induced visceral pain in Swiss albino mice.”

• One of the cheapest models.
• Repurposing angle makes the project more current.
• Add formalin test if funds allow, so that you have two complementary pain models.

Best topics depending on your external examiner

My updated top 3 under ₹10,000

1. Metformin plus paracetamol in formalin-induced persistent pain - 9.2/10
2. Melatonin plus paracetamol in formalin-induced persistent pain - 8.9/10
3. Famotidine versus pantoprazole against diclofenac-induced gastric injury - 8.6/10

One topic I would choose if I were you

“Evaluation of the paracetamol-sparing effect of low-dose metformin in formalin-induced persistent inflammatory pain in Swiss albino mice, with motor-safety assessment.”

• A clear clinical question
• Drug repurposing
• Combination pharmacology
• Low expense
• Easy, defendable endpoints
• A good opportunity to discuss dose-sparing and pharmacodynamic interaction

“A systematic literature search will determine whether this exact drug combination, dose design, animal model, and outcome set has previously been reported.”

Different M.Pharm pharmacology project ideas

Best completely different ideas for your external

1. Best overall: stress, stomach injury and behaviour

“Evaluation of propranolol as a repurposed agent in restraint stress-induced gastric injury and behavioural alteration in Swiss albino mice.”

• It links the brain-gut axis, stress pharmacology, autonomic system, and ulcer pharmacology.
• It is more interesting than only doing an ulcer index.
• Propranolol is cheap and familiar, but its role in your exact integrated model can be the research gap.
• You can discuss sympathetic activation, catecholamines, stress-induced gastric mucosal injury, and behavioural outcomes.

---

2. Best metabolic-CNS project

“Effect of short-term metformin treatment on high-fat-diet-induced glucose intolerance and anxiety-like behaviour in mice.”

• Combines metabolic dysfunction and behavioural pharmacology.
• Modern angle: metabolic disease can affect mental health-related behaviour.
• Has two meaningful outcomes: glucose regulation and anxiety-like behaviour.
• More advanced than a basic antidiabetic project.

---

3. Smart and very low-cost: metformin chronopharmacology

“Chronopharmacological evaluation of metformin on oral glucose tolerance in Swiss albino mice.”

• Uses a modern concept: drug response may vary with biological timing.
• Low reagent and drug cost.
• Strong viva points: circadian rhythms, glucose metabolism, pharmacodynamics, and rational dosing time.
• Does not need expensive biochemical kits if glucose estimation is available.

---

4. Different and practical: caffeine withdrawal model

“Evaluation of behavioural and locomotor consequences of short-term caffeine withdrawal in Swiss albino mice.”

• Very inexpensive.
• Relevant to a widely consumed psychoactive substance.
• You can discuss adenosine receptors, dependence, withdrawal, anxiety, and motor activity.
• Better if you compare caffeine exposure, withdrawal, and control groups.

---

5. Strong CNS option: seizure threshold

“Evaluation of pyridoxine pretreatment on pentylenetetrazole-induced seizure threshold in Swiss albino mice.”

• Moves away from routine pain studies.
• Good neuropharmacology discussion: GABA synthesis, seizure threshold, and anticonvulsant screening.
• Uses inexpensive drugs and clear endpoints.

My final new top 5

1. Propranolol in restraint-stress-induced gastric injury and behavioural alteration - 9.0/10
2. Metformin in high-fat-diet glucose intolerance plus anxiety-like behaviour - 8.9/10
3. Chronopharmacology of metformin in oral glucose tolerance - 8.8/10
4. Pyridoxine plus metformin in glucose intolerance - 8.7/10
5. Caffeine withdrawal and anxiety-like behaviour - 8.6/10

Best one to submit to your guide

“Evaluation of propranolol as a repurposed agent in restraint stress-induced gastric injury and behavioural alteration in Swiss albino mice.”

“Stress activates sympathetic and neuroendocrine pathways that may affect both behaviour and gastric mucosal integrity. This project evaluates whether modulation of adrenergic signalling alters these linked stress outcomes.”

Best different rat-based project topics under ₹10k

Best topic for rat and external examiner

Recommended final title

Why it can impress an external

• It is a direct comparison of two clinically relevant drug classes: H2-receptor blocker versus proton-pump inhibitor.
• It uses a clinically meaningful stress-related ulcer model, rather than only a routine acid-secretion model.
• You can discuss stress physiology, autonomic activation, gastric acid, mucosal defence, and comparative pharmacology.
• Endpoints are objective and affordable: ulcer index, lesion number/severity, gastric pH, and acidity if your laboratory permits.
• It is much more feasible than ferroptosis or chemotherapy-neuropathy projects.

Best if you want a modern, clean project with minimum cost

Title

Why it is strong

• Modern concept: drug response may change with dosing time.
• Very low drug and reagent cost.
• Clear numerical data: fasting glucose, post-glucose values, glucose AUC.
• Easy to explain in viva: circadian rhythm, glucose metabolism, pharmacodynamics, and rational timing of therapy.
• Less invasive and ethically simpler than ulcer or seizure models.

Best CNS-focused rat project

Title

Topics I would avoid with rats under ₹10k

• Streptozotocin diabetes plus neuropathy projects
• High-fat diet metabolic syndrome models
• Chronic unpredictable stress for many weeks
• Histopathology-dependent topics if external pathology fees apply
• ELISA, cytokine, oxidative stress, ferroptosis, PCR, or Western blot studies
• Paclitaxel neuropathy and postbiotic projects
• Any claim of a mechanism without the assay to measure it

Final ranking for you

1. Famotidine vs pantoprazole in restraint-stress gastric injury
   Best rat project for clinical relevance and external impression.
2. Metformin chronopharmacology with OGTT
   Best low-cost, clean, modern project with reliable numerical data.
3. Propranolol in restraint stress, gastric injury, and behavioural change
   Most novel-looking integrated pharmacology project, but only if you have behavioural apparatus.
4. Magnesium sulphate plus sodium valproate in PTZ seizures
   Strong CNS topic, but higher ethical and technical responsibility.

Option 1: Comparative evaluation of famotidine and pantoprazole against restraint-stress-induced gastric mucosal injury in Wistar rats.

Option 2: Chronopharmacological evaluation of metformin on oral glucose tolerance in Wistar rats.

Unique rat project topics with ratings

Top 5 distinctive choices

1. Best overall: ondansetron and gastrointestinal motility

“Evaluation of low-dose ondansetron on gastric emptying and intestinal transit in Wistar rats.”

• Not a routine analgesic, antidiabetic, or anti-ulcer study.
• Connects antiemetic pharmacology with the clinically relevant adverse effect of constipation or slowed gut movement.
• Uses affordable measurable endpoints.
• Gives good viva discussion on serotonin receptors, enteric nervous system, upper versus lower gastrointestinal motility, and drug adverse effects.

• Percentage gastric emptying
• Percentage intestinal transit
• Stool number and fecal water content, if you extend the study

---

2. Best integrated project: stress, glucose and gastric injury

“Evaluation of propranolol as a modulator of restraint stress-induced hyperglycaemia and gastric mucosal injury in Wistar rats.”

• Tests one drug across two linked outcomes of stress physiology.
• Strong pharmacology story: sympathetic activation, catecholamines, blood glucose, mucosal circulation, and β-adrenergic blockade.
• Uses inexpensive drugs and basic measurements.

---

3. Most unusual low-cost idea: furosemide chronopharmacology

“Chronopharmacological evaluation of furosemide-induced diuresis in Wistar rats.”

• Simple, objective data.
• Not overused in student projects.
• You can discuss circadian biology, renal physiology, pharmacodynamics, and rational timing of diuretic therapy.
• Does not require biochemical kits if you only measure urine volume, onset, and duration.

---

4. Best autonomic-pharmacology idea

“Comparative evaluation of cetirizine and levocetirizine on locomotor activity, motor coordination and exploratory behaviour in Wistar rats.”

• Clear comparison of commonly used second-generation antihistamines.
• Practical relevance: residual sedation and psychomotor impairment.
• Low cost and safer than ulcer or seizure models.
• Reliable data if actophotometer and rotarod are available.

---

5. Best constipation project

“Comparative evaluation of lactulose and magnesium sulphate in loperamide-induced constipation in Wistar rats.”

• Strong clinical relevance.
• More useful than simply proving a laxative works.
• Easy endpoints: fecal count, fecal water, charcoal-meal transit.
• Lets you compare osmotic laxatives with different practical pharmacology.

My final recommendation

1. Low-dose ondansetron on gastric emptying and intestinal transit in Wistar rats
2. Propranolol in restraint stress-induced hyperglycaemia and gastric mucosal injury
3. Chronopharmacology of furosemide-induced diuresis

“Chronopharmacological evaluation of furosemide-induced diuresis in Wistar rats.”

“Evaluation of low-dose ondansetron on gastric emptying and intestinal transit in Wistar rats.”

“No study was identified during the literature search that evaluated this exact drug, dose, model, and outcome combination.”

Best 5 unique choices

1. Ondansetron-induced GI motility alteration

“Evaluation of ondansetron-induced alteration in gastrointestinal motility and its reversal by a prokinetic agent in Wistar rats.”

• Looks clinically relevant because constipation is a practical adverse effect of 5-HT3 antagonists.
• Covers both adverse-effect pharmacology and rescue therapy.
• Strong viva discussion: serotonin receptors, enteric nervous system, gastric emptying, intestinal transit, antiemetic adverse effects.
• Does not require ELISA, PCR, histopathology, or expensive kits.

---

2. Iron preparation-associated constipation

“Comparative evaluation of oral iron preparations for constipation-like effects and intestinal transit in Wistar rats.”

• Iron-associated gastrointestinal intolerance is clinically important.
• Compares safety, rather than only testing efficacy.
• Different from routine pharmacology projects.
• Cheap if standard iron salts are available.

• Ferrous sulphate
• Ferrous fumarate
• A better-tolerated preparation available locally

---

3. Isoniazid plus pyridoxine neurobehavioural safety

“Effect of pyridoxine supplementation on isoniazid-induced neurobehavioural toxicity in Wistar rats.”

• Directly connected to a real clinical preventive practice.
• Allows a high-quality pharmacology discussion: vitamin B6, GABA synthesis, isoniazid toxicity, peripheral neuropathy and seizure risk.
• Better than simply testing anticonvulsant activity.

---

4. Furosemide chronopharmacology

“Chronopharmacological comparison of furosemide-induced diuresis in Wistar rats.”

• Objective, clean numerical data.
• Very low reagent cost.
• Distinct topic that few student projects select.
• You can discuss circadian rhythm, renal physiology, diuretic pharmacodynamics, and rational dosing time.

---

5. Caffeine withdrawal: brain-gut pharmacology

“Effect of short-term caffeine withdrawal on anxiety-like behaviour, locomotor activity, and gastrointestinal transit in Wistar rats.”

• Connects CNS and gastrointestinal pharmacology.
• Caffeine is inexpensive and familiar.
• Lets you explain adenosine receptors, tolerance, withdrawal, anxiety, and gut motility.
• More interesting than only measuring locomotor activity.

My honest final recommendation

“Evaluation of ondansetron-induced alteration in gastrointestinal motility and its reversal by a prokinetic agent in Wistar rats.”

“Chronopharmacological comparison of furosemide-induced diuresis in Wistar rats.”

“Effect of pyridoxine supplementation on isoniazid-induced neurobehavioural toxicity in Wistar rats.”

“No study was identified evaluating this exact drug, dose schedule, rat model, and combined endpoint set during the structured literature search.”

A less commonly studied disease model + a clinically relevant drug problem + a precise low-cost endpoint set.

Unique disease-based rat topics

Top 3 best choices

1. NSAID-induced small-intestinal enteropathy

“Evaluation of famotidine versus pantoprazole on indomethacin-induced small-intestinal enteropathy and intestinal transit in Wistar rats.”

• Most student projects study only gastric ulcers.
• This focuses on the relatively neglected small-intestinal injury caused by NSAIDs.
• You can explain that reducing acid does not automatically prove protection in the small intestine.
• It combines adverse-drug-reaction pharmacology, gastrointestinal pharmacology, and intestinal motility.
• No costly molecular assays are required if you use gross lesion scoring and transit testing.

---

2. Oral iron-associated constipation-like bowel dysfunction

“Comparative evaluation of ferrous sulphate and ferrous fumarate on constipation-like bowel dysfunction and intestinal transit in Wistar rats.”

• Oral iron causes clinically important gastrointestinal intolerance.
• This evaluates drug safety and tolerability, not merely efficacy.
• It is different from routine anti-ulcer, antidiabetic, analgesic, and anti-inflammatory projects.
• Drugs and endpoints are low-cost.
• You can discuss formulation choice, adherence, adverse effects, and intestinal motility.

---

3. Ondansetron-associated delayed GI transit

“Evaluation of a prokinetic approach against ondansetron-associated delayed gastric emptying and intestinal transit in Wistar rats.”

• Ondansetron is widely used as an antiemetic, while constipation and slowed bowel movement are clinically relevant adverse effects.
• It has a good pharmacological story: 5-HT3 antagonism, enteric nervous system, motility, adverse-effect management.
• It provides two objective outcomes: gastric emptying and intestinal transit.
• It is more distinctive than a standard laxative study.

My strongest recommendation

“Comparative evaluation of famotidine and pantoprazole on indomethacin-induced small-intestinal enteropathy and intestinal transit in Wistar rats.”

Simple low-cost outcomes

1. Body-weight change
2. Small-intestinal lesion number and lesion score
3. Intestinal transit using charcoal meal
4. Fecal occult blood, only if low-cost kits are available
5. Gross photograph documentation of intestinal lesions

Important caution

“A structured literature search will assess whether the selected intervention has been evaluated in this exact rat model, with this dose schedule and these combined gastrointestinal outcome measures. The proposed study addresses this specific evidence gap.”

“No published study was identified for this exact drug, dose, disease model, and endpoint combination after a structured PubMed and Scopus search.”

Unique and relatively rare disease-syndrome topics in rats

Top 3 that will impress an external

1. NSAID-induced small-intestinal enteropathy

“Comparative evaluation of selected gastroprotective strategies in indomethacin-induced small-intestinal enteropathy and altered intestinal transit in Wistar rats.”

• Small-intestinal lesion number and severity score
• Intestinal length
• Body-weight change
• Charcoal-meal intestinal transit
• Gross photographs of lesions

---

2. Functional dyspepsia-like delayed gastric emptying

“Evaluation of a repurposed prokinetic strategy in restraint-stress-induced functional dyspepsia-like delayed gastric emptying in Wistar rats.”

• Percentage gastric emptying
• Intestinal transit
• Food intake
• Body-weight change
• Anxiety-like behaviour only if your department has open-field or elevated-plus-maze apparatus

---

3. Cyclophosphamide-induced haemorrhagic cystitis

“Evaluation of [selected low-cost repurposed drug] against cyclophosphamide-induced haemorrhagic cystitis in Wistar rats.”

• Bladder weight
• Urine colour or haematuria score
• Gross bladder lesion score
• Water intake and urine output
• Body-weight change

---

Best final pick for you

Select this if you want maximum uniqueness within ₹10k:

“Evaluation of a repurposed gastroprotective strategy in indomethacin-induced small-intestinal enteropathy and altered intestinal transit in Wistar rats.”

• gastric ulcer models
• carrageenan paw oedema
• diabetes models
• analgesic screening
• routine constipation models

What not to select despite sounding rare

• Fabry disease
• Pompe disease
• Wilson disease
• Huntington disease
• Duchenne muscular dystrophy
• Spinal muscular atrophy
• Pulmonary arterial hypertension
• Pulmonary fibrosis
• Chronic kidney disease with vascular calcification
• Endometriosis
• Parkinsonism with molecular markers

How to make the rare topic scientifically strong

• Random allocation of rats to groups
• Blinded lesion and behavioural scoring
• A standard comparator drug
• One primary endpoint, decided before starting
• One safety or functional endpoint
• Clear humane endpoints and IAEC approval

Rare and unique rat disease-topic ideas

Best rare topic to impress your external

1. Tardive dyskinesia-like syndrome

“Evaluation of [selected repurposed drug] in haloperidol-induced tardive dyskinesia-like oro-facial dyskinesia in Wistar rats.”

Why it is strong

• Tardive dyskinesia is a serious, often persistent adverse effect of chronic antipsychotic therapy.
• It is much more unusual than routine analgesic, ulcer, antidiabetic, or anti-inflammatory studies.
• It provides an excellent viva discussion on dopamine receptor blockade, dopamine receptor supersensitivity, oxidative stress hypothesis, abnormal involuntary movements, and adverse drug reaction management.
• You can measure visible behavioural outcomes without ELISA, PCR, or histology.
• It is a proper neuropharmacology and pharmacovigilance project.

Practical outcomes

• Frequency of vacuous chewing movements
• Tongue protrusions
• Facial jerking or chewing episodes
• Locomotor activity
• Rotarod performance, to separate dyskinesia from general motor impairment

Second-best rare topic

Cyclophosphamide-induced haemorrhagic cystitis

“Evaluation of a low-cost uroprotective intervention against cyclophosphamide-induced haemorrhagic cystitis in Wistar rats.”

Third-best rare topic

Isoniazid-associated neurotoxicity

“Effect of pyridoxine dosing schedule on isoniazid-induced peripheral neurobehavioural toxicity in Wistar rats.”

Best shortlist for your guide

1. Haloperidol-induced tardive dyskinesia-like oro-facial dyskinesia in Wistar rats
   Best for external impression and neuropharmacology viva.
2. Cyclophosphamide-induced haemorrhagic cystitis in Wistar rats
   Best rare supportive-care topic, but needs cytotoxic-drug safety capability.
3. Isoniazid-induced peripheral neurobehavioural toxicity in Wistar rats
   Best tuberculosis-drug-safety project.
4. Indomethacin-induced small-intestinal enteropathy in Wistar rats
   Best gastrointestinal adverse-drug-reaction project.
5. Stress-induced functional dyspepsia-like delayed gastric emptying in Wistar rats
   Best brain-gut pharmacology project.

My final recommendation

“Evaluation of [test drug] in haloperidol-induced tardive dyskinesia-like oro-facial dyskinesia in Wistar rats.”

“No study was identified evaluating this exact intervention, dose schedule, haloperidol exposure protocol, and behavioural outcome panel in Wistar rats.”

• Scientific relevance and novelty
• Strength of pharmacology concept
• Clinical relevance
• Feasibility in an M.Pharm lab
• Suitability for approximately ₹10,000
• Quality of viva discussion

Ranking of your topics

Best topic to impress an external

1. NSAID-induced small-intestinal enteropathy

“Comparative evaluation of selected protective strategies in indomethacin-induced small-intestinal enteropathy and altered intestinal transit in Wistar rats.”

Why it is the strongest

• Most students choose an NSAID gastric ulcer model. Your project addresses the less-discussed small-intestine injury.
• It demonstrates understanding of adverse drug reactions, gastrointestinal pharmacology, intestinal motility, and limitations of routine gastroprotection.
• It gives you excellent viva points:
  • Why gastric protection may not equal intestinal protection
  • NSAID-related injury beyond the stomach
  • Importance of intestinal transit as a functional endpoint
  • Drug safety rather than only drug efficacy
• It can be assessed at low cost with lesion scoring, intestinal length, body weight, charcoal transit, and gross photographs.

---

Best if you want a rare disease-like syndrome

2. Functional dyspepsia-like delayed gastric emptying

“Evaluation of a repurposed prokinetic drug in restraint-stress-induced functional dyspepsia-like delayed gastric emptying in Wistar rats.”

• Stress physiology
• Brain-gut axis
• Functional dyspepsia
• Gastric dysmotility
• Rational repurposing of a prokinetic drug

• Percentage gastric emptying
• Charcoal-meal intestinal transit
• Food intake
• Body weight
• Behavioural observation if open-field apparatus is available

---

Best rare neuropharmacology topic

3. Tardive dyskinesia-like syndrome

“Evaluation of [selected repurposed drug] in haloperidol-induced tardive dyskinesia-like oro-facial dyskinesia in Wistar rats.”

• Your guide has already performed the haloperidol model.
• You can maintain the chronic dosing schedule.
• You have access to an actophotometer or rotarod.
• You can score vacuous chewing movements in a blinded manner.

---

My final selection order for you

If your priority is highest external impression:

1. NSAID-induced small-intestinal enteropathy - 9.3/10
2. Functional dyspepsia-like delayed gastric emptying - 9.1/10
3. Haloperidol-induced tardive dyskinesia-like syndrome - 9.0/10

If your priority is low cost and successful completion:

1. Metformin chronopharmacology with OGTT - 8.7/10
2. Oral iron-associated bowel dysfunction - 8.8/10
3. Metformin-paracetamol low-dose combination - 8.6/10

Avoid under ₹10k

• Diabetic neuropathy plus ferroptosis
• Postbiotic therapy in chemotherapy neuropathy
• Cyclophosphamide cystitis unless the institution provides cytotoxic-drug facilities

My one best recommendation

“Evaluation of a repurposed prokinetic drug in restraint-stress-induced functional dyspepsia-like delayed gastric emptying in Wistar rats.”

“No published study was identified that evaluated this exact intervention, dose schedule, restraint-stress model, and combined gastric-emptying and intestinal-transit outcomes.”These are much more advanced than routine rat projects. They can strongly impress an external examiner, but only if your department has the required C. elegans or zebrafish facility, trained guide, microscopy/imaging access, and validated disease strains. Otherwise, an external may see the title as ambitious but incomplete.

Ratings of the four topics

---

1. Best choice: Zebrafish larval drug screen for Dravet syndrome

Rating: 9.5/10 for external impression

Better title

“Phenotype-guided screening of repurposed small molecules in a zebrafish larval model of Dravet syndrome.”

“Evaluation of selected repurposed small molecules in a scn1lab-deficient zebrafish larval model of Dravet syndrome.”

Why it will impress an external

• Dravet syndrome is a severe developmental and epileptic encephalopathy, not a routine seizure model.
• It uses a modern, ethical, high-throughput vertebrate model.
• It involves drug repurposing, rare-disease pharmacology, larval behaviour, and seizure phenotype assessment.
• Zebrafish research can generate several outcomes: locomotor hyperactivity, seizure-like behaviour, survival, morphology, and toxicity.
• It provides excellent viva points about SCN1A-related disease, sodium-channel dysfunction, translational screening, and the 3Rs.

Main risk

• Zebrafish breeding and larval-maintenance system
• A validated scn1lab mutant or equivalent Dravet line
• Stereo microscope and behavioural recording setup
• Personnel trained in zebrafish husbandry and scoring

---

2. Alternating hemiplegia of childhood in C. elegans

Rating: 9.1/10 for external impression

Better title

“Pharmacological evaluation of selected repurposed small molecules in a Caenorhabditis elegans model of ATP1A3-related alternating hemiplegia of childhood.”

Why it is strong

• Alternating hemiplegia of childhood is a very rare ATP1A3-related neurodevelopmental disorder.
• C. elegans is a low-cost model with good suitability for early-stage drug screening.
• It demonstrates knowledge of rare disease, genetic disease modelling, repurposing, and simple organism pharmacology.
• It is less expensive and easier to scale than rat or zebrafish work.

Major correction

“No study was identified evaluating this defined panel of repurposed small molecules in the selected ATP1A3-variant C. elegans model using the specified behavioural and neuromuscular outcome panel.”

Main risk

---

3. Statin repurposing for an ultra-rare glycosylation disorder

Current rating: 8.8/10 potential, but only 5/10 as currently written

“Repurposing a statin for an ultra-rare glycosylation disorder.”

• Which congenital disorder of glycosylation?
• Which gene defect?
• Which statin?
• Why should inhibition of HMG-CoA reductase help that condition?
• What model will be used?
• What phenotype will improve?
• How will glycosylation or disease phenotype be measured?

How to make it strong

“Evaluation of [specific statin] in a [specific gene]-deficient C. elegans or zebrafish model of [named congenital disorder of glycosylation].”

1. A suitable disease model exists in your department or collaborator lab.
2. The statin has a published mechanistic rationale.
3. You have a measurable phenotype: locomotion, survival, developmental delay, morphology, mitochondrial function, or other validated readout.

Verdict

---

4. “Sensitised drug screen in a particular C. elegans model”

Current rating: Not rateable

Disease or gene + sensitising condition + test-drug library + measurable phenotype

“Sensitised screening of repurposed drugs in a C. elegans model of [named rare disease] using [specific stressor or genetic sensitisation] and locomotor recovery as the primary endpoint.”

---

Final ranking for you

Choose this if your college has zebrafish facilities

1. Dravet syndrome zebrafish larval drug screen

Choose this if your college has a C. elegans laboratory but no zebrafish facility

2. ATP1A3-related alternating hemiplegia of childhood in C. elegans

Avoid selecting now

3. Statin in rare glycosylation disorder

My recommendation

“Phenotype-guided screening of selected repurposed small molecules in a scn1lab-deficient zebrafish larval model of Dravet syndrome.”

Ratings for external-examiner impression

Best choice: Letrozole-induced PCOS in rats

Refined title

“Evaluation of [selected low-cost intervention] on ovarian morphology and metabolic dysfunction in letrozole-induced polycystic ovary syndrome in female Wistar rats.”

Why it will impress the external

• PCOS is clinically important and combines reproductive endocrinology, metabolic pharmacology, and histopathology.
• The letrozole rat model is well known and defensible. It can reproduce hyperandrogenic and ovarian features, while metabolic outcomes require proper model design and measurement.
• You can present multiple integrated outcomes:
  • Estrous-cycle irregularity by vaginal cytology
  • Ovarian weight and morphology
  • Ovarian histology, if your college provides it
  • Body-weight change
  • Fasting glucose and oral glucose-tolerance test
  • Optional lipid profile only if funding permits
• It is easier to explain and defend than an exploratory areca-nut neurotoxicity model.

Main limitation

1. A scientifically justified, defined test intervention
2. A focused question
3. Proper metabolic and ovarian outcomes
4. Good study design

Best low-cost intervention options

• Myo-inositol: clinically relevant but confirm cost
• Metformin as positive-control or comparator: useful, but not your novel test drug
• Vitamin D, only if you can justify baseline deficiency or a clear mechanistic question
• N-acetylcysteine, clinically relevant antioxidant/insulin-sensitising rationale, but check cost
• Pyridoxine or magnesium, lower-cost but need a strong literature-based reason

---

Why Topic 1 is weaker despite sounding unique

Your proposed topic

“Areca nut-induced neurobehavioural changes and oxidative stress in mice: evaluation of a protective intervention.”

Strengths

• Areca nut use is regionally and clinically relevant.
• It is less commonly selected than PCOS.
• It can produce an interesting pharmacovigilance or toxicology story.

Problems an external may ask

1. Which areca preparation? Raw nut, extract, arecoline, pan masala-like mixture?
2. What human exposure does your dose represent?
3. Which neurobehavioural domain? Anxiety, cognition, locomotion, dependence, depression-like behaviour?
4. What proves oxidative stress? You need at least validated biochemical markers such as MDA, reduced glutathione, SOD, or catalase.
5. Which protective intervention and why?
6. Is it a validated mouse model?

---

Final decision

Choose Topic 2 if you want:

• Better marks
• Easier viva
• Strong disease relevance
• Clear and measurable endpoints
• A more reliable project outcome

Choose Topic 1 only if:

• Your guide has already worked with areca-nut or arecoline animal exposure
• You have access to oxidative-stress assays
• You can specify the exact exposure substance and neurobehavioural outcomes

Best viva statement for Topic 2

“PCOS is not solely an ovarian disorder. It is a reproductive-metabolic syndrome characterised by ovarian dysfunction and insulin-resistance-related metabolic abnormalities. This study evaluates whether a defined low-cost intervention improves both ovarian morphology and metabolic dysfunction in a validated letrozole-induced rat model, with metformin as the pharmacological comparator.”

1. C. elegans model of alternating hemiplegia of childhood
2. Statin repurposing for an ultra-rare congenital disorder of glycosylation
3. Zebrafish larval screen for Dravet syndrome
4. Sensitised drug screen in a specific C. elegans model
5. Areca-nut-induced neurobehavioural toxicity in mice
6. Letrozole-induced PCOS in rats

Overall ranking to impress an external examiner

My clear recommendation

Choose Topic 1 overall, only if the laboratory already has zebrafish infrastructure:

“Phenotype-guided evaluation of selected repurposed small molecules in a scn1lab-deficient zebrafish larval model of Dravet syndrome.”

• A severe rare paediatric disease
• A disease-relevant genetic model
• Drug repurposing
• Modern larval behavioural screening
• A 3Rs-aligned model
• A direct translational rationale

Choose Topic 2 if you do not have zebrafish:

“Pharmacological evaluation of selected repurposed small molecules in a Caenorhabditis elegans model of ATP1A3-related alternating hemiplegia of childhood.”

Choose Topic 3 if your department requires rats:

“Evaluation of [defined low-cost intervention] on ovarian morphology and metabolic dysfunction in letrozole-induced polycystic ovary syndrome in female Wistar rats.”

• Vaginal cytology
• Ovarian morphology or histology
• Body weight
• Fasting glucose and OGTT
• Metformin as standard comparator

Final decision rule

• Zebrafish facility + scn1lab line available: Choose Dravet zebrafish - 9.5/10
• C. elegans facility + validated ATP1A3 model available: Choose AHC worm model - 9.2/10
• Only standard rat laboratory available: Choose letrozole-PCOS rat project - 8.7/10
• No validated model or specialised facility: Do not select statin-glycosylation or vague sensitised-screen topics.Assuming the top 6 are these:

1. Zebrafish Dravet syndrome drug screen
2. C. elegans model of alternating hemiplegia of childhood
3. Statin repurposing in a congenital disorder of glycosylation
4. Sensitised drug screen in a C. elegans disease model
5. Areca-nut-induced neurobehavioural toxicity in mice
6. Letrozole-induced PCOS in rats

Direct comparison

Best ranking by criterion

Best for novelty

1. Statin in a defined congenital disorder of glycosylation
2. AHC in C. elegans
3. Dravet syndrome zebrafish screen
4. Sensitised C. elegans screen, only after defining the disease
5. Areca neurotoxicity
6. PCOS rat model

Best for feasibility under ₹10,000

1. AHC in C. elegans, if strain and worm facility exist
2. Sensitised C. elegans screen, only if your lab already has the model
3. Dravet zebrafish, only if mutant line and zebrafish facility exist
4. Letrozole-PCOS rats, if animal house and histology support are provided
5. Areca neurotoxicity in mice
6. Statin-glycosylation disorder, unless it is a fully supported collaborative project

Best for external-examiner impression

1. Dravet syndrome zebrafish screen - 9.5/10
2. AHC C. elegans model - 9.2/10
3. Letrozole-PCOS rat model - 8.7/10
4. Statin-glycosylation topic - 8.5/10 potential, but only 5/10 if vague
5. Areca neurotoxicity model - 7.8/10
6. Unspecified sensitised screen - not suitable until properly defined

My practical recommendation

If your college has a validated C. elegans disease strain and a guide experienced in worm work:

“Pharmacological evaluation of selected repurposed small molecules in a Caenorhabditis elegans model of ATP1A3-related alternating hemiplegia of childhood.”

If your college already has zebrafish, a scn1lab mutant line, behavioural recording, and trained staff:

“Phenotype-guided evaluation of selected repurposed small molecules in a scn1lab-deficient zebrafish larval model of Dravet syndrome.”

If you have only a standard animal house with rats:

“Evaluation of [defined low-cost intervention] on ovarian morphology and metabolic dysfunction in letrozole-induced PCOS in female Wistar rats.”

Do not select these without clarification

Statin for glycosylation disorder

• The exact disorder and causative gene
• The selected statin
• Why a statin is mechanistically justified
• The available validated model
• The measurable disease phenotype

Sensitised C. elegans drug screen

Disease gene + worm strain + sensitising condition + drug panel + primary phenotype

Final answer

1. ATP1A3-related alternating hemiplegia of childhood in C. elegans
2. Lafora disease in epm2a-deficient zebrafish larvae
3. N-acetylcysteine intervention in letrozole-induced PCOS in Wistar rats

---

1. C. elegans model of Alternating Hemiplegia of Childhood

Final title

Key feasibility requirement

Experimental plan

Step 1: Select strains

• Wild-type control strain
• Validated AHC mutant strain, for example a heterozygous eat-6 knock-in corresponding to an ATP1A3 disease variant
• If available, more than one mutant allele can be included, but for an M.Pharm project one robust mutant allele is enough

Step 2: Synchronise worms

• Maintain worms according to the host laboratory’s standard worm-culture SOP.
• Obtain age-synchronised animals.
• Use the same developmental stage for every group, usually young adults or the stage used by the source laboratory.
• Confirm normal bacterial food source, temperature, and plate conditions across groups.

Step 3: Select repurposed compounds

• Neuronal excitability
• Ion-homeostasis modulation
• Calcium handling
• Neuromuscular transmission
• Existing human safety information

1. Wild-type plus vehicle
2. Mutant plus vehicle
3. Mutant plus each test compound
4. Optional wild-type plus the most promising compound, to identify non-specific toxicity

Step 4: Tolerability and concentration-range study

• Test a small concentration range of each compound in wild-type worms.
• Observe survival, movement, developmental progression, and visible toxicity.
• Select concentrations that do not cause paralysis, developmental delay, marked lethality, or severe locomotor suppression.

Step 5: Primary phenotype evaluation

• Locomotor activity
• Thrashing/swimming behaviour
• Crawling speed
• Neuromuscular-junction functional assay
• Response to a standard cholinergic or neuromuscular challenge, only if already validated locally

Step 6: Secondary outcomes

• Survival
• Developmental stage
• Body length or growth proxy
• Reproductive capacity, if feasible
• General movement in wild-type worms
• Sleep/arousal-like phenotype only if your lab has a validated assay

Step 7: Blinding and analysis

• Randomize treatment plates.
• Code the plates so the scorer does not know the genotype or drug.
• Perform at least 2 to 3 independent biological repeats.
• Predefine the primary endpoint before data collection.
• Compare genotype, treatment, and genotype-treatment interaction.

Expected outcome

• Improve mutant locomotor or neuromuscular phenotype
• Not reduce wild-type movement
• Not delay development
• Not increase mortality

Strong viva statement

“The study uses a genetically defined ATP1A3-equivalent model to identify whether selected clinically used small molecules can rescue a quantifiable neuromuscular phenotype. We distinguish genuine phenotypic rescue from non-specific sedation, developmental delay, or toxicity.”

---

2. Zebrafish larval screen for Lafora disease

Final title

Important correction

Key feasibility requirement

• A zebrafish facility
• An existing epm2a-deficient zebrafish line
• Embryo collection and larval rearing support
• Stereo microscope
• Behavioural tracking system or video-recording system
• Guide trained in zebrafish larval screening

Experimental plan

Step 1: Prepare and identify larvae

• Breed heterozygous or mutant adult fish according to local fish-facility SOP.
• Collect embryos and maintain them in approved embryo medium.
• Stage larvae by hours or days post fertilisation.
• Identify mutant and control larvae by facility-approved genotype or breeding strategy.
• Use larvae at the same developmental stage for all experiments.

Step 2: Select a focused drug panel

• Neuronal hyperexcitability
• Glucose/glycogen-related biology
• Autophagy-lysosomal pathways
• Oxidative-stress modulation
• Existing CNS safety profile

1. Wild-type plus vehicle
2. Lafora-model larvae plus vehicle
3. Lafora-model larvae plus test drug 1
4. Lafora-model larvae plus test drug 2
5. Lafora-model larvae plus test drug 3
6. Optional reference compound, only if scientifically justified

Step 3: Determine maximum tolerated concentration

• Expose normal larvae to a concentration range of each candidate.
• Observe mortality, heart rate if the facility routinely measures it, gross morphology, swimming ability, and developmental delay.
• Select a dose that is tolerated and does not suppress normal locomotion.

Step 4: Drug exposure

• Expose larvae to vehicle or test compound in a coded and randomized manner.
• Keep solvent concentration identical across all groups.
• Maintain identical light-dark cycle, temperature, and medium conditions.
• Use the exposure window already validated by the local facility.

Step 5: Behavioural assessment

• Total distance moved
• Average swim velocity
• High-velocity burst events
• Seizure-like swimming episodes
• Immobility duration
• Response during light-dark transition, if used by your facility

Step 6: Confirm hits

• Repeat in at least two independent larval clutches.
• Confirm that survival and morphology remain normal.
• If available, perform local-field-potential recording or another electrophysiological method to verify reduced seizure-like activity.

Step 7: Analysis

• Treat individual larvae as experimental units only if exposure and tracking are independent.
• Include clutch as a possible biological variable.
• Compare mutant vehicle versus mutant treatment first.
• Also compare treated wild-type larvae to assess toxicity/sedation.
• Report mortality and excluded tracking files.

Expected outcome

• Reduce mutant hyperactivity or seizure-like burst events
• Preserve normal larval survival and morphology
• Not suppress locomotion in wild-type larvae
• Show similar benefit in independent repeat experiments

Strong viva statement

“The model is used as a phenotype-guided first-pass screen. A compound is considered a genuine pharmacological hit only when it improves the mutant behavioural phenotype without causing sedation, developmental toxicity, or mortality.”

---

3. Letrozole-induced PCOS in female Wistar rats

Final title

Why this is the most practical topic

• Standard animal-house project
• Clear disease relevance
• Easily understood in viva
• Multiple low-cost outcomes
• Strong reproductive plus metabolic pharmacology story

Suggested experimental groups

Detailed procedure

Phase 1: Animal selection and acclimatisation

• Use adult female Wistar rats with regular estrous cycles.
• Acclimatise animals under standard laboratory conditions.
• Record baseline body weight.
• Assess estrous cyclicity by vaginal cytology before randomisation.
• Include animals showing regular cycling according to the local validated method.

Phase 2: Randomisation

• Randomly allocate eligible animals to study groups.
• Use a coding method so the person examining vaginal smears and ovarian samples is blinded to group allocation.
• Record all exclusions before starting treatment.

Phase 3: PCOS induction

• Induce PCOS using your IAEC-approved letrozole protocol.
• Letrozole is commonly administered orally in a suitable vehicle such as carboxymethylcellulose.
• A published protocol used letrozole 1 mg/kg/day orally with standard chow or high-fat diet, but your guide must select the final regimen based on the local model validation and ethics approval. The 2025 model study illustrates this type of approach.
• Monitor body weight and general health regularly.

Phase 4: Confirm PCOS-like phenotype

• Persistent estrous-cycle irregularity
• Increased body weight or altered weight gain
• Ovarian morphological changes, if feasible
• Fasting glucose or impaired oral glucose tolerance, depending on the model

Phase 5: Intervention treatment

• Administer N-acetylcysteine using the final guide-approved route, dose, and duration.
• Administer metformin reference treatment to the standard group if included.
• Give vehicle to control groups on the same schedule.
• Monitor body weight, feed intake if feasible, and overt toxicity.

Phase 6: Estrous-cycle assessment

• Collect vaginal smears at the same time each day.
• Stain and identify predominant cell populations using your departmental SOP.
• Record the proportion of time spent in each estrous phase.
• Persistent diestrus or irregular cycles support PCOS-like reproductive dysfunction.

Phase 7: Metabolic assessment

Fasting blood glucose

• Conduct only according to animal ethics approved fasting duration.
• Measure fasting glucose using validated glucometer strips or laboratory estimation.

Oral glucose tolerance test

• Record fasting baseline glucose.
• Administer the approved oral glucose load.
• Measure blood glucose at pre-specified time points in the approved protocol.
• Calculate glucose area under the curve, which is more informative than reporting a single glucose reading.

Phase 8: Ovarian assessment

1. Collect ovaries
2. Record ovarian weight
3. Note gross appearance
4. If histology is available:
   • Fix tissue using local pathology SOP
   • Prepare H&E-stained sections
   • Blind the assessor
   • Count or score:
     • Cystic follicles
     • Corpora lutea
     • Follicular development
     • Stromal thickening or hyperplasia, if applicable

Phase 9: Statistical analysis

• Glucose AUC, if metabolic dysfunction is your main focus, or
• Blinded ovarian histology score, if pathology support is available

• Estrous-cycle regularity
• Body-weight change
• Fasting glucose
• Ovarian weight
• Cystic follicle count
• Corpus luteum count

Expected outcome

• Irregular estrous cyclicity
• Ovarian cystic changes
• Reduced corpora lutea
• Increased body weight or metabolic dysfunction
• Impaired glucose tolerance

Strong viva statement

“This project evaluates PCOS as a reproductive-metabolic syndrome rather than only an ovarian condition. We assess estrous cyclicity, ovarian morphology, fasting glucose, and oral glucose tolerance, while using metformin as a pharmacological reference where feasible.”

Best choice by infrastructure

• C. elegans facility and validated AHC strain available: choose AHC worm model
• Zebrafish facility and epm2a mutant line available: choose Lafora disease model
• Only regular pharmacology animal house and budget around ₹10k: choose letrozole-PCOS rat study1. AHC in C. elegans
  • Primary 2026 eat-6/ATP1A3 knock-in model paper
  • Recent AHC mouse-model and clinical-context papers
  • What phenotypes and screening endpoints support a drug-repurposing project

1. Lafora disease in epm2a-deficient zebrafish
   • Core zebrafish model and treatment-validation studies
   • Behavioural, seizure-like, molecular, and safety endpoints
   • Model limitations, especially early larval absence of Lafora bodies
2. Letrozole-induced PCOS in female Wistar rats
   • Recent validation papers comparing letrozole alone versus letrozole plus high-fat diet
   • Evidence for reproductive and metabolic endpoints
   • How to select a defensible, low-cost design for an NAC project